Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph. D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and LSD. Dr. Johnson teaches us what the clinical trials in his lab are revealing about the potential these compounds hold for the treatment of depression, addiction, trauma, eating disorders, ADHD, and other disorders of the mind. Dr. Johnson describes a typical psychedelic experiment in his laboratory, start to finish, including the conditions for optimal clinical outcomes. And he explains some of the potential hazards and common misconceptions and pitfalls related to psychedelic medicine. Dr. Johnson explains flashbacks, the heightened risks of certain people and age groups using psychedelics and the ever evolving legal and pharmaceutical industry landscape surrounding psychedelics. Dr. Johnson also explains how the scientific study of psychedelics is likely to set the trajectory of psychiatric medicine in the years to come. Dr. Johnson is among a small handful of researchers who have pioneered the clinical study of these powerful compounds. He has unprecedented insight into how they can be woven into other psychiatric treatments, changing ones sense of self and of reality. Read the full show notes for this episode at hubermanlab.com. Thank you to our sponsors AG1: https://athleticgreens.com/huberman LMNT: https://drinklmnt.com/hubermanlab Waking Up: https://wakingup.com/huberman Momentous: https://livemomentous.com/huberman Timestamps 00:00:00 Introducing Dr. Matthew Johnson 00:02:27 Sponsors: AG1, LMNT & Waking Up 00:06:40 ‘Psychedelics’ Defined 00:14:09 Hallucinations, Synesthesia, Altered Space-Time Perception 00:19:56 Serotonin & Dopamine 00:23:50 Ketamine & Glutamate 00:28:00 An Example Psychedelic Experiment 00:37:30 ‘Letting Go’ with Psychedelics 00:44:10 Our Mind’s Eye 00:48:00 Redefining Your Sense of Self 00:58:56 Exporting Psychedelic Learnings to Daily Life 01:04:36 Flashbacks 01:12:10 Ayahuasca, ASMR, Kundalini Breathing 01:15:54 MDMA, DMT 01:26:00 Dangers of Psychedelics, Bad Trips, Long-Lasting Psychosis 01:38:15 Micro-Dosing 01:56:45 Risks for Kids, Adolescents & Teenagers; Future Clinical Trials 02:03:40 Legal Status: Decriminalization vs. Legalization vs. Regulation 02:18:35 Psychedelics for Treating Concussion & Traumatic Brain Injury 02:27:45 Shifting Trends in Psychedelic Research, Academic Culture 02:44:23 Participating in a Clinical Trial, Online Survey Studies, Breathwork 02:50:38 Conclusions, Subscribing & Supporting the HLP, Supplements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Andrew D. Huberman?

  Welcome to the Huberman Lab Podcast where we discuss science and science-based tools for everyday life.

• 0:09Andrew D. Huberman?

  I'm Andrew Huberman and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. Today, I have the pleasure of introducing Dr. Matthew Johnson. Dr. Johnson is a professor of psychiatry at Johns Hopkins School of Medicine, where he also directs the Center for Psychedelic and Consciousness Research. As many of you know, there's extreme excitement about the use of psychedelics for the treatment of various disorders of the mind. Dr. Johnson's laboratory is among the premier laboratories in the world, understanding how these compounds work, how things like psilocybin and LSD and related compounds allow neural circuitry in the brain to be shaped and change such that people can combat diseases like

• 0:50Andrew D. Huberman?

  depression, or trauma, or other disorders of the mind that cause tremendous suffering. Dr. Johnson is also an expert in understanding how different types of drugs impact different types of human behaviors, such as sexual behavior, risk-taking, and crime. Dr. Johnson and his work have also been featured prominently in the popular press, such as articles in the New York Times, in Michael Pollan's book, How to Change Your Mind, and in a feature in 60 Minutes about psychedelics and the new emerging science of psychedelic therapies for treating mental disorders. During the course of today's conversation, Dr. Johnson and I talk about psychedelics at the level of what's called microdosing, whether or not it is useful for the treatment of any mental disorders.

• 1:33Andrew D. Huberman?

  We also talk about more typical macrodosing, what those macrodoses entail, and he walks us through what an experiment of a patient taking psychedelics for the treatment of depression looks like in his laboratory from start to finish. The conversation was an absolutely fascinating one for me to partake in. I learned so much about the past, present, and future of psychedelic treatments and compounds. And indeed, I hope to have Dr. Johnson on this podcast again in the not-too-distant future, so that we can talk about other compounds that powerfully impact the mind and human behavior, and perhaps can also be used to treat various diseases. Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford.

• 2:16Andrew D. Huberman?

  It is, however, part of my desire and effort to bring zero cost to consumer information about science and science-related tools to the general public. In keeping with that theme, I'd like to thank the sponsors of today's podcast.

• 2:29Speaker 01

  Nordstrom Rack is celebrating 125 years of Nordstrom with 125 of the best deals, up to 65% off in stores and online. They're only here while supplies last, so shop today. Great brands, great prices. That's why you rack.

• 2:47Speaker 02

  Mr. President, my company foreme of the explosion on our rig.

• 2:50Speaker 03

  On October 2nd.

• 2:51Speaker 02

  Causing massive water displacement and triggering a tsunami. They all heap the blame on me.

• 2:56Speaker 03

  Tom Cruise is. Digger got us into this mess, and Digger's gonna dig us up. From the director of Birdman and The Revenant.

• 3:03Speaker 04

  What would happen if I stopped going? You stall, you freeze to death, that's what.

• 3:08Speaker 03

  With great power comes great deniability.

• 3:11Speaker 04

  I'm not the first nanny.

• 3:12Speaker 03

  Digger. See the trailer online. Only in theaters October 2nd. Rated R. Under 17. Not a minute without parent.

• 3:17Speaker 05

  If high-interest credit card debt is keeping you up at night, you're not alone. Interest rates as high as 21% APR can do that to you. Rocket Mortgage can help. A home equity loan from Rocket Mortgage could cut your interest rate by more than half, so you could wipe out your high-interest credit card debt without touching your current mortgage rate. See how much you could save at rocketmortgage.com. Rocket Mortgage LLC, licensed in 50 states. NMLS Consumer Access.org, number 3030. Call 8004ROCKET for full program details.

• 3:48Speaker 06

  Hey, Spotify listeners. When you travel with American Airlines, you'll enjoy comfort and convenience at every altitude. Before takeoff, unwind in the Admirals Club Lounge with curated self-serve offerings of hearty bites and refreshments. In flight, stay connected with high-speed Wi-Fi. Sponsored by AT&T. Your journey is designed to feel easy from the moment you check in to the moment you arrive. No matter where you're going, American gets you there. Book now at aa.com.

• 4:13Andrew D. Huberman?

  And now, my conversation with Dr. Matthew Johnson. Well, Matthew, I've been looking forward to this for a long time. I'm a huge fan of your scientific work, and I'm eager to learn from you.

• 4:25Speaker 07

  Likewise, big fan and happy to do this with you.

• 4:28Andrew D. Huberman?

  Okay, well, thank you. My first question is a very basic one, which is, what is a psychedelic? We hear this term all the time, but what qualifies a substance as a psychedelic?

• 4:40Speaker 07

  Nomenclature is a real challenge in this area of psychedelics. So, starting with the word psychedelic, it just, if you're a pharmacologist, it's not very satisfying, because that term really spans different pharmacological classes. In other words, if you're really concerned about receptor effects and the basic effects of a compound, it spans several classes of compounds. But overall, so it's really more of a cultural term, or it does have a relationship to drug effects, but it's at a very high level.

• 5:19Speaker 07

  So, all of the so-called psychedelics across these distinct classes that I can talk more about, the way I put it is, they all have the ability to profoundly alter one's sense of reality, and that can mean many things. Part of that is profoundly altering the sense of self, acutely. So, when someone's on the psychedelic. So, the different classes that can be, the specific pharmacological classes that can be called a psychedelic are, one, what are called the classic psychedelics. So, in the literature, you'll see that term. And hallucinogen and psychedelic are all, have traditionally been used synonymously.

• 6:04Speaker 07

  I think there was a little bit of a tendency to stay away from psychedelics as a baggage, but there's been a return to that in the last several years. But the classic psychedelics or classic hallucinogens are things like... LSD, psilocybin, which is in so-called magic mushrooms. It's in over 200 species that we know of so far of mushrooms. Dimethyltryptamine, or DMT, which is in dozens and dozens of plants. Mescaline, which is in the peyote cacti and some other cacti like San Pedro. And even amongst these classic psychedelics, there are two structural, structural classes. So that's the chemistry.

• 6:46Speaker 07

  There's the tryptamine-based compounds like psilocybin and DMT. And then there's the phenethylamine-based compounds. So these are the basic, two basically building blocks that you're starting from, either a tryptamine structure or a phenethylamine structure. But that's just the chemistry, that all of the, what's more important, or at least to someone like me, are the receptor effects. And then ultimately, that's going to have a relationship to the behavioral and subjective effects. So all of these classic psychedelics serve as agonists or partial agonists at the serotonin two-way receptor, so subtype of serotonin receptor. Then you have these other classes of, that you, compounds that you could call psychedelic.

• 7:31Speaker 07

  Another big one would be the NMDA antagonist. So this would include ketamine, PCP, and dextromethorphan, something I've done some research with, which folks might recognize from like robo-tripping, guzzling, like, you know, colseric, which is something kind of like high school kids are known to do and they can't get a hold of real drugs, that type of thing. So a large overlap in the types of subjective effects that you get from those compounds compared to the two-way agonist classic psychedelics. But then you have, and by the way, this description, this framework I'm describing, not everyone will agree. Some people will say, no, psychedelic only means classic psychedelic. So there's different opinions here.

• 8:16Speaker 07

  But you have, gosh, salvinorane, which is a kappa opioid agonist, which

• 8:22Speaker 07

  Where does that come from? Salvio diva normum. It's a plant that became 20 years ago. It sort of popped onto the legal high scene. And there's a, you know, long history of this. Predating the internet, going back to like the stuff one could order in the back of High Times Magazine. And most of this stuff like never worked, you know? It's like the smoke enough of anything, maybe you get a little bit lightheaded. But this is one of those things that popped around 20 years ago when it quickly got the reputation of like, holy shit, this stuff actually works and works really strongly. And these smoked extracts particularly, people have these reality altering experiences on par with smoked DMT, the classic psychedelic.

• 9:03Speaker 07

  So often, and we did the first blinded controlled human research with Salvino Renee. So lots of entity contact, so feeling that you, in the experience of one is actually interacting with autonomous beings, that type of thing. And then you have another big one, I probably should have mentioned even before the, you know, Salvino Renee. But you have MDMA, which really stands in a class by itself. So it's been called an intactogen and, and. What does that mean? It means like touching within. It's sort of alludes the idea that it can really put someone in touch with their emotions. It's also been called in an pathogen, meaning can afford empathy.

• 9:47Speaker 07

  But I think intactogen is probably that's the term that I, I tend to focus on. And I know I'm not telling you anything you don't know, but the, for the, for the viewers, the, the primary mechanism of MDMA is serotonin release and to a degree other monoamine release, dopamine, serotonin. And so structurally, that's also in the phenethylamine class, which contains mescaline, the classic psychedelic, but also amphetamine. So just like Adderall is, is, is. In that phenethylamine class, and so this is another example where chemistry doesn't dictate. I mean, you can tweak a molecule, it might have that same basic

• 10:30Speaker 07

  structure, but now you've profoundly changed the way it interacts with the receptors. So MDMA does not, you know, exert its actions by, I like to say, by mimicking the baseball entering the glove, the postsynaptic receptor side, you know, acting as an agonist, so mimicking the endogenous neurotransmitter serotonin, like the classic psychedelics do. MDMA works on the pitcher's side of just basically throwing out more of the natural, the endogenous.

• 11:06Andrew D. Huberman?

  Dumping more serotonin.

• 11:06Speaker 07

  Dumping more serotonin, flooding the synapse.

• 11:10Andrew D. Huberman?

  So I get the impression that the psychedelic space is a enormous cloud of partially overlapping compounds.

• 11:17Speaker 07

  Right.

• 11:18Andrew D. Huberman?

  Meaning some are impacting the serotonin system more than the dopamine system, others are impacting the dopamine system more than the serotonin system. Given that the definition of a psychedelic is that it profoundly alters sense of self, at least that's included as a partial definition. Can we break that down into a couple of subcategories? So for instance, hallucinating, either auditory or visual. Synesthesia, perceptual blending, the sense that, you know, you can hear colors and see sounds, for instance, a common report of people that take psychedelics in sufficiently high doses.

• 12:01Andrew D. Huberman?

  So hallucinating, synesthesia, and then in terms of sense of self, you know, as a neuroscientist, I think, okay, what does it mean to alter a sense of reality? Really, what the brain does in a very coarse way is to try and figure out what's happening in space, physical space, and that physical space could be within us or outside us, and what's happening in time.

• 12:24Speaker 07

  Right.

• 12:25Andrew D. Huberman?

  And as a vision scientist, the simplest explanation is when I move my hand from one location to another location, it's measuring the space, the location of my hand in space, over time. And then you get a rate and a, you know, speed and all that kind of stuff, right?

• 12:38Speaker 07

  Yeah.

• 12:40Andrew D. Huberman?

  That gets more complicated as you get into the emotional realm. But is it fair to say that psychedelics are impacting the space-time analysis that the brain is performing and thereby creating hallucinations and thereby altering, you know, the blending of senses? Is it fair to say that?

• 13:03Speaker 07

  I think it's it's fair to explore that area. And here's what I'm thinking. The the clearly there is a changed relationship, certainly at the right dose, of orientation and space-time. I think as a, you know, I'm primarily a behaviorist and in terms of pharmacology, human behavioral pharmacology, I always go to comparative pharmacology. What can we say that is it truly unique about the classic psychedelics or psychedelics in general? So with that description, I'm thinking, okay, alcohol can really screw up your, you know, time-space orientation.

• 13:39Andrew D. Huberman?

  And proprioception, your balance, vestibular.

• 13:42Speaker 07

  You know, and in many ways, and in those gross motorways, like far worse, you know, of course, everything's dose-dependent, but in the classic psychedelics, you know, obviously the benzodiazepines, being very similar alcohol, same thing. So, you know, I'd want to, you know, dig in a little more in terms of like, maybe there's something more specific we could say about that relationship to time and space that the psychedelics are tinkering with. But I'm not sure. It's an interesting hypothesis, the idea that that's a mediator, that that's something, that there's something fundamental about changing that, the representation in time and space. There might be something to that.

• 14:23Speaker 07

  I think of these as psychedelics as profoundly altering models, you know, you know, we're all, you know, we're prediction machines and that's large, so much of that is top-down and psychedelics have a good way of, you know, loosely speaking, dissolving those models. And one of the reality.

• 14:47Andrew D. Huberman?

  Can you give us an example of one of, like a model? Like I know that when I throw a ball in the air, it falls down, not up. That's a, that's a prediction that I learned as a child that I, I did not come into the world with a brain that um knew that relationship between objects and gravity. But one of the first things that a child learns is the relationship between objects and gravity and their trajectories.

• 15:14Speaker 07

  Yeah, and with a four-year-old, I mean, I saw that at earlier ages, like that experimentation of like, oh, yeah, that's what happens, you know?

• 15:22Andrew D. Huberman?

  Right, so if he were to throw, if your child were to throw a ball and it went up into the sky, that would be absolutely mind-blowing. It would be for an adult, too.

• 15:33Speaker 07

  It'd be a pretty psychedelic experience, probably.

• 15:35Andrew D. Huberman?

  Right, and so there's a, there's a, there's a rule there, you're saying, there's a kind of a, a prediction. There's a rule that, that underlies a prediction that when that rule is violated, all of a sudden the circuit presumably for that prediction go like, it doesn't have a mind of its own, but somehow it creates a surprise element or a, or a recognition element?

• 15:57Speaker 07

  And it's not filtered out, you know, uh, and this might sound extreme, but there are these cases, it was over, overblown in sort of the propaganda, the late sixties, early seventies, but there are credible cases of people, and it's very atypical of sounds like they really thought they could fly and, you know, jump out of a, a, a, of a window. Now, far more people every year fall, I mean, who knows, you know, they, they, they, they fall and die out of, you know, from height because they're drunk, you know, so this is extremely rare. But, you know, there are some like pretty convincing um cases. There was one research volunteer in our studies that uh,

• 16:41Speaker 07

  it, she looked like she was in one of our studies, like she was trying to dive through a painting on the wall. She was fine, but she, reviewing the video, it looked like she really thought that she was gonna go through that painting and Who knows?

• 17:00Andrew D. Huberman?

  So she was

• 17:01Speaker 07

  Into the other dimension.

• 17:02Andrew D. Huberman?

  Yeah, so they're violating these predictions. Yeah, I, the reason I ask it, the, the question the way I did is because, um, given the enormous cloud of different substances and given the range of previous experiences that people show up to a psychedelic experience with, uh, I feel like the ability to extract some universal themes is, is useful, especially for people who haven't done them before, right? Who might not have an understanding of what their effects are like. Can we just briefly touch on the serotonin system?

• 17:35Speaker 07

  Mm hmm.

• 17:36Andrew D. Huberman?

  And the dopamine system? I, I want to acknowledge that, as you already know, that there are many neuromodulator systems in the body and, you know, the opioid systems, cannabinoid systems, but there's something so profound about the serotonin system and the dopamine system because the way I define a neuromodulator is it's a modulator, it changes the way that other circuits behave. And essentially it up, it increases the probability that certain circuits will be active and decreases the probability that other circuits will be active in, in a, in a general sense. So, compounds like LSD, myseric acid, diethylamide, and psilocybin, my understanding is that they primarily target the serotonin system.

• 18:19Andrew D. Huberman?

  How do they do that at a kind of general level? And why would increasing the activity of a particular serotonin receptor or batch of serotonin receptors lead to these profoundly different experiences that we're calling, um, model challenges, challenging pre-existing models and predictions? I mean, at the end of the day, it's a chemical and these receptors are scattered around the brain with billions of other receptors.

• 18:46Speaker 07

  Yeah.

• 18:47Andrew D. Huberman?

  Uh, what do we think is going on in a general sense?

• 18:51Speaker 07

  Yeah, yeah. And this is really the area of active exploration and we don't have great answers. We know a good amount about the receptor level pharmacology, some things about Post-receptor signaling pathways, in other words, just fitting into the receptor. Clearly, serotonin itself is not psychedelic, you know, or else we'd be tripping all of us all the time.

• 19:12Andrew D. Huberman?

  Because when I eat a bagel, I get serotonin release, right?

• 19:15Speaker 07

  Uh huh.

• 19:15Andrew D. Huberman?

  I mean, there's, or turkey, I mean, there's tryptophan, right? My understanding of serotonin is that in very broad strokes, that it generally leads to a state of being fairly, it pushes the mind and body towards a state of contentment within the immediate experience. Whereas the dopamine system really places us into an external view of what's out there in the world and what's possible.

• 19:40Speaker 07

  Yeah.

• 19:41Andrew D. Huberman?

  Is that fair to say?

• 19:42Speaker 07

  Need to do something. I mean, that's consistent with my understanding. And I'll certainly not in terms of, I don't primarily identify as a neuroscientist. Definitely tell the, you know, the viewers that we're far more in your domain here than mine. But in terms of how psychedelics and other drugs, you know, interface at the neuroscience level.

• 20:02Andrew D. Huberman?

  Well, feel free to explain it at the experiential level.

• 20:05Speaker 07

  Yeah.

• 20:06Andrew D. Huberman?

  I mean, it doesn't have, I think there probably are some audience members that are interested in, is it the 5H2C? Is it the layer five neurons and cortex? That conversation we could hold, and that's an interesting conversation. But just in terms of the experience of serotonergic versus dopaminergic drugs.

• 20:23Speaker 07

  Yeah.

• 20:23Andrew D. Huberman?

  They, they do seem to create distinct classes of experience. So I think that's, that's the appropriate level for us to discuss them.

• 20:32Speaker 07

  And in terms of how they, and I'd like to explore the biology a little bit here and tell you like sort of what's known and what some of the ideas are.

• 20:39Andrew D. Huberman?

  Please.

• 20:40Speaker 07

  Um, you have this path, you know, as you know, like, you know, these are levels of analysis and it's not which one is going on. It's almost like for the particular question, which level of analysis is most appropriate to? Is it, you know, is a question best addressed by the biology, the chemistry or the physics? That's how I think of like receptor level, post-receptor signaling, downstream effects on other neurotransmitters and then.

• 21:05Speaker 07

  In activation level effects and then coordination of activation. So you've got the clearly the with the classic psychedelics, the two A activation. We do know that there are downstream effects in terms of increasing glutamate transmission. So this is likely a commonality. Why, you know, ketamine is very psychedelic in slightly different way.

• 21:28Andrew D. Huberman?

  Do people hallucinate on ketamine?

• 21:30Speaker 07

  Yes, yes. And it's more dissociative. So someone is more likely to sort of be less behaviorally active. If they have a really high dose, they go into a K hole. And if they go in a really high dose, like you get into surgery, you're just unconscious. Yeah.

• 21:43Andrew D. Huberman?

  Not an A hole, but a K hole.

• 21:45Speaker 07

  A K hole. Yeah, it's very different.

• 21:49Speaker 07

  The K hole and ketamine is interesting because people can take kind of bumps and kind of dance on it with the sort of an alcohol level strength of effect. And that's sort of the classic kind of raving, you know, use of it. But then those folks want to titrate their dose because if they do more of like a line, you get up to like 75, 100 milligrams, then you're talking about, you know, if you're on the dance floor, you're on the floor and your friends are trying to make sure people aren't stepping on you. So that's like.

• 22:17Andrew D. Huberman?

  Yeah, why would somebody want to take a dissociative anesthetic? Like to me, it's completely mysterious as to why someone will want to dissociate from their body.

• 22:28Speaker 07

  People claim that these, these, the, these NMDA antagonists psychedelics are extremely insightful, you know, in a very similar way to the experiences with the classic psychedelics. So.

• 22:39Andrew D. Huberman?

  And ketamine is now legal for therapeutic use.

• 22:41Speaker 07

  Right, right. Spravato, the, the, the intranasal form marketed by Janssen, which is esketamine.

• 22:49Andrew D. Huberman?

  It's prescription.

• 22:50Speaker 07

  Yeah, it's prescription and.

• 22:53Andrew D. Huberman?

  So people are taking in the nasal spray.

• 22:55Speaker 07

  Yeah.

• 22:55Andrew D. Huberman?

  And then are they undergoing talk therapy while they're doing this?

• 22:58Speaker 07

  Typically not. So it's, this is very interesting and there's so much work that needs to be done. It's not treated as psychedelic therapy. And by that psychedelic therapy, I mean. You tell the person they're gonna have an altered experience. You tell them to pay attention to that experience. That they might learn something from that experience. And afterwards, you discuss that experience. With Spravato, the model is Spravato is? Is esketamine. Okay. It's the, yeah, the spray form of ketamine. It's been FDA approved for treatment resistant depression. But it's, you'll, you'll probably feel different. Ignore that. That's a side effect. That's an adverse effect. Just ignore it. We don't think that has anything to do with the way it works.

• 23:44Speaker 07

  But just get this thing. It's, it's a direct, you know, sort of chemotherapeutic effect in a sense. It's, it's, it's not facilitating a learning process. Now, there's older work. There was a guy Kropitsky in Russia that did extensive work with higher doses of ketamine. I should say Spravato at the prescribed doses isn't very, it's a pretty low dose. It's in the mild psychedelic range, but it's not very strong. But this older work that happened in the nineties and early two thousands in, in Russia, they were using very high doses and treating it like a psychedelic, treating it as if it was a psychedelic therapy. In other words, telling people, you're gonna have this experience. It's gonna, you know, we're hoping you learn something from it. We're gonna help you through it.

• 24:29Speaker 07

  We're gonna discuss it afterwards. And they found incredibly high rates of success and some pretty well-controlled trials for both heroin addiction and alcohol addiction. So I think a whole lot of work needs to be done now. And you see some of the ketamine clinics that are using ketamine off-label, a lot of them are treating it like psychedelic therapy. There's essentially no research at this point on that. Do you get better results? Straight abuse of Spravato, there's some good variability, but its antidepressant effects last about a week. But they kick in immediately. Now, a week is a long time for like most, most psychiatric drugs. Like you take it every day. Right. You know, so that's amazing, but it's still just a week. We're seeing effects.

• 25:13Speaker 07

  A year or more later with psilocybin and some of the classic psychedelics, that could be a pharmacological difference, or it could be that they get a lot more mileage out of ketamine if they treated it like psychedelic therapy.

• 25:27Andrew D. Huberman?

  What would that look like?

• 25:30Speaker 07

  Really, just like our psilocybin sessions, which I know I haven't described, but briefly, you have anywhere from four to eight hours of preparation, getting to know the people who are going to be the guides or the therapists in the room.

• 25:42Andrew D. Huberman?

  Yeah, maybe you could walk us through this. So, let's say I were to come to one of your clinical trials, because these are clinical trials, right? At your lab at Hopkins. And would I need to be depressed, or could I just be somebody who wanted to explore psychedelics?

• 25:57Speaker 07

  We've had studies for all of these, and a number of other disorders. So, healthy, normal studies, the code for not a problem to fix, but we're all here. That's what's amazing about psychedelics, though, because if you administer them under this model, and you develop a relationship and give a high dose of psychedelic, you can be healthy, normal, without a diagnosable issue. But, man, we're all human, and the issues seem to come to the surface. But we've done work with smoking cessation, so people trying to quit tobacco and haven't been successful.

• 26:27Andrew D. Huberman?

  So, a variety of reasons. So, maybe, I'll just ask some very simple questions that would kind of step us through the process. So, let's say I were to sign up for one of these trials, and I qualified for one of these trials, I'd show up. You said I would do several hours in advance of getting to know the team that would be present during this psychedelic journey.

• 26:45Speaker 07

  First, there's screening, so it's kind of like a couple of days of both psychiatric, like structured psychiatric interviews about your whole, your past, and symptoms across the DSM, the psychiatric bible, to see if you might have various disorders that could disqualify you, like the main ones being the psychotic disorders, schizophrenia, and also including bipolar, so the manic side of bipolar. So, after that, and also cardiovascular screening, heart disease, after that screening, then the preparation, where you get, you're both, you develop a therapeutic rapport with the people who are going to be in the room with you, your guides, but you're also then, didactically... Sort of explained about what the psychedelic could be like.

• 27:30Speaker 07

  And that's kind of a laundry list because they're more known by their variability. Then, you know, it's gonna, it's not like cocaine, like you're gonna feel stimulated. You're gonna feel like, you know, you can do any, it's like, you know, or alcohol, you're gonna, probably gonna feel more relaxed. It's like, I call them uppers, downers, and all-rounder's, and the psychedelics are all-rounder's. It's like, yeah, you could be, you could have the most beautiful experience of your life, or the most terrifying experience of your life. So it's this kind of laundry list of like, the things that could happen, so there's no surprises.

• 28:04Andrew D. Huberman?

  I think it's so important for people to hear because the all-rounder's, they, the, you really can't predict how somebody is going to react internally.

• 28:13Speaker 07

  Right.

• 28:14Andrew D. Huberman?

  I wanna just briefly touch on something, because we, we left that topic, but

• 28:21Andrew D. Huberman?

  it occurred to me that a lot of these effects of psychedelics and how they function, et cetera, is still very mysterious. But then, I recall to mind that how most prescription antidepressants work is also very mysterious. They increase serotonin, or dopamine, or epinephrine, et cetera. But why they take weeks on, and, you know, several weeks to kick in, et cetera, is also mysterious. But going back to the, the, the experience of, of coming to your laboratory. Okay, so, let's say that somebody passes all the prerequisites. And, and it's the day.

• 28:53Speaker 07

  Yeah.

• 28:53Andrew D. Huberman?

  Comes the day that they're going to have this experience. Are they eating mushrooms like you hear about? Or are they taking it in capsule form? And how, what sorts of doses are you prescribing? Is there a dose-response curve?

• 29:08Speaker 07

  Yeah.

• 29:09Andrew D. Huberman?

  And then, secondary to that, I'd like to talk about microdose versus macrodose. So, how do they get this stuff into, how do people receive it? And how do they get it into their body?

• 29:20Speaker 07

  So they receive pure psilocybin. So, the mushroom, and there are many species, the most, people have taken mushrooms in the United States. It's, it's most likely psilocybin cubensis. They're easy to grow, they grow in cow patties, it's easy for any. Body to grow them in their closet. It doesn't take a thousand watt light like cannabis. It takes like a little, you know, 10 watt light bulb and a Tupperware bin. So those are what, those are the types of mushrooms that people typically take. We're not administering those. Psilocybin is the compound. You could draw a molecule, psilocybin, again, based on the tryptamine structure. Like, that's a single molecular entity. So it's a white powder.

• 30:00Andrew D. Huberman?

  Does it look like serotonin molecularly?

• 30:02Speaker 07

  Yes, yes, yes.

• 30:04Andrew D. Huberman?

  So if I looked at, if I were to show people the chemical structure of serotonin, the chemical structure of psilocybin, it would look quite similar.

• 30:11Speaker 07

  Right, right.

• 30:11Andrew D. Huberman?

  So they're basically taking serotonin.

• 30:14Speaker 07

  It, a modified version of serotonin, which makes sense. But then, again, this repeated theme of the chemistry doesn't always neatly line up because like mescaline looks more like, like dopamine than it does like serotonin. But yet, it, at the receptor activation level, the pharmacologic, neuropharmological effect, it's, those are similar. But, but yeah, I mean, and what it does at the receptor is an alternate, it's, it's, it's hitting the same switch, but then having an alternate response at the receptor.

• 30:48Andrew D. Huberman?

  Yeah, so for people that don't necessarily understand the relationship between what we call ligand, the thing that parks in the receptor, and the receptor is the parking spot. One of the reasons that you can get such a variety of effects from different compounds is, for instance, serotonin might affect a certain pathway at a particular rate. And psilocybin might trigger activation of different components of that pathway at different rates since you can get vastly different experiences from two things that look chemically similar. This is also a good reason why people shouldn't just assume that they can cowboy their own chemistry. Right? That what you see on paper and what you can mix up in a vial is often vastly different than what you predict.

• 31:32Speaker 07

  Right. And there's a dose effect curve that's really interesting. Some of our early work with psilocybin in healthy normals, looked at a true placebo plus four active doses, five, 10, 20, and 30 milligrams of psilocybin. Body weight adjusted, so, you know, those milligrams per 70 kilograms of body weight. We've recently published a paper in our newer trials. We're, we're dropping the body weight adjustment because our, going across hundreds of volunteers. We've kind of figured out that. That you shouldn't really be, you don't need to be adjusting by body weight.

• 32:06Andrew D. Huberman?

  Interesting.

• 32:07Speaker 07

  So, so, yeah.

• 32:08Andrew D. Huberman?

  Well, brain size doesn't vary that much between individuals.

• 32:11Speaker 07

  Yeah, yeah.

• 32:13Andrew D. Huberman?

  You know, at the end, this is a brain effect, mostly, probably body as well. Um, okay, so the person ingests the, the powder or capsule?

• 32:23Speaker 07

  Yeah, and it doesn't take, thirty milligrams is a small, you could fit it into a tiny little capsule. And, and it'll take about a half hour, but I mean, we're from fifteen minutes to an hour to kick in.

• 32:34Andrew D. Huberman?

  And you said the dose range was?

• 32:38Speaker 07

  Most of our studies are, are looking at where we, we want a psychedelic effect are in the twenty to thirty milligram range. Um, again, because we have adjusted by body weight and the average American is over seventy kilograms, about a hundred and fifty pounds, like people, and in fact have gotten more like, you know, forty, forty-five in a lot of cases. But, um, it's still a small pill. Um, there, the, the session day itself is not full of, for most of our studies is not full of tasks. We really want to look at the therapeutic response. Obviously, if it's a therapeutic study, we want it to be a meaningful experience and, uh, research has found, not surprisingly, that you get a less meaningful experience when you're in an FMRI

• 33:23Speaker 07

  or when you're doing a lot of cognitive tasks. Um, we've done some research on, on, you know, of, of that type for sure, and plenty of colleagues have. But when you're in a therapeutic study or if you're trying to understand the therapeutic effects, you, you have to recognize there's this, this, this trade-off of, of what you can do. So our typical therapeutic model, which again isn't just limited necessarily to the therapeutic studies where we're trying to treat a specific disorder, um, it, it is, is to, you know, have that preparation so you, the person feels very comfortable with their guides. Um, uh, I mean, ultimately, what I tell people is like, any emotional response, it's all welcome.

• 34:02Speaker 07

  I mean, you could, you could be crying like a baby hysterically, like that's what you should be doing if that's what you feel like. And so, in a lot of ways, sometimes people with psychedelic experience uh, on their own. It can be harder to train them in this model because in the real world, people with psychedelic experience, a lot of times the rule is, you know, hold your shit. So, you know, several friends go to a party, they split a bag of mushrooms. It's like, you know, there's a social pressure for good reason not to be the guy, you know, in the corner of the room where everyone's trying to just have a good time, relax, like crying about your mother, your other friends are, they're having an experience too, and you're being a drama king and blah, blah, blah. And so like, yeah, compose yourself, hold your people.

• 34:46Andrew D. Huberman?

  You're doing, I mean, you're doing therapy for people. This is, it's not just about the experience.

• 34:51Speaker 07

  Right, and the experience itself is very much shaped by, by that, that container, by the environment and the degree to which one allows it to happen. Like, one should let go of control.

• 35:03Andrew D. Huberman?

  Yeah, let's talk about the, the letting go of control. And then as we march through this hypothetical experience that does take place in your lab. But we're using a sort of generic case example, if you will. The letting go of control is an interesting feature, actually, because one of the common themes of, of good psychoanalysis is, or psychotherapy of any kind, is that there's a trust built between the patient and the analyst. And that relationship becomes a template for trust more generally and trust in oneself. It's actually the, the end goal of good psychoanalysis is that the patient actually, one of the end goals is that they develop an empathy for themselves, which almost sounds like an oxymoron, but if you spend a little time with that statement,

• 35:47Andrew D. Huberman?

  it, it actually pans out. So, the psychedelic experience is one in which chemically you're under a new, new set of conditions, right?

• 36:00Speaker 07

  Yeah.

• 36:00Andrew D. Huberman?

  Let's, coarsely, space and time are, are altered in some ways, sense of self. For instance, I might be going to a strongly interoceptive mode where I'm focusing on everything within the confines of my skin, whereas normally we're sort of interacting in space and pens and conversation. And I'm sort, if I had, occasionally I'll pay attention to my breathing, but I'm sort of dilating my, and contracting my focus for different things all the time. The letting go of control, it seems to me, could be sort of the expansion of one perceptual bubble to the point where you're not actually worried that that perceptual bubble is gonna pop, or that, meaning, you're not worried about what people think of you.

• 36:40Speaker 07

  Yeah.

• 36:41Andrew D. Huberman?

  You're not worried whether or not your brain is gonna explode, even though a thought could feel enormous.

• 36:46Speaker 07

  Mm-hmm.

• 36:47Andrew D. Huberman?

  If I keep going like this, it almost sounds psychedelic, but that's the idea here. Or if I'm paying attention, for instance, to some somatic experience, like the coursing of waves of heat through my body, that I'm not suddenly saying, you know, is that weird? I'm actually just going deeper and deeper into it. So it's essentially expanding a perceptual phenomenon. How do you convince people to go further and further down that path? What do you think allows them to do that? Because I think that, to me, is one of the more unusual aspects to psychedelics, is that normally, the social pressure, but also just our internal pressure from our own brain, is pay attention to many things at once, not just one.

• 37:32Andrew D. Huberman?

  Is that...

• 37:33Speaker 07

  Especially these days. Yeah, multitask.

• 37:36Andrew D. Huberman?

  Exactly. Right. Multitask, and the more that we focus on one thing, the more bizarre that thing actually can appear to us, right?

• 37:42Speaker 07

  Right.

• 37:43Andrew D. Huberman?

  I mean, even if it's the tip of your finger and you're not taking any psychedelics, you spend a long enough looking at the tip of your finger, you will notice some very weird things, right?

• 37:51Speaker 07

  That's, I think of that as the classic psychedelic effect, or one classic effect, and one I've used many times of this example of why people shouldn't necessarily, you know, these aren't, these, one should be judicious in putting themselves in these circumstances. Someone could be, you know, having a very strong psilocybin experience, and they're trying to navigate their way in Manhattan, crossing the street, and they might be staring into their hand and real, like, that's, their hand is the most amazing miracle. Like, the entire universe has essentially conspired to come to this one point, to make this absolutely breathtaking, it's almost like, I think of the simplest form of, well,

• 38:35Speaker 07

  we know the simplest form of learning is habituation, simply keep applying stimuli and there's less response, like... This is what organisms do, this is what we have to do. And it's like, there's this dis-habituation component that like-

• 38:46Andrew D. Huberman?

  Dis-habituation.

• 38:47Speaker 07

  Yes, like we wouldn't be able to get through life if, we wouldn't be able to cross that street if we were like, "Oh, like, this is a miracle."

• 38:54Andrew D. Huberman?

  Well, I'm so glad you- No, I'm so glad you brought this up. I mean, here I'm reflecting my bias as a vision scientist, but most people don't realize this, but if you look at something long enough, it eventually disappears. It doesn't actually disappear, but perceptually it disappears. You have these little micro-saccades that ensure that it doesn't.

• 39:10Speaker 07

  Right.

• 39:10Andrew D. Huberman?

  But most of us don't look at any one thing for very long.

• 39:13Speaker 07

  Right.

• 39:14Andrew D. Huberman?

  The, the brain's default is to perceptually jump around like crazy with the visual system, with the auditory system. We all, ADD, and people talk about ADD a lot, is sort of baked into our underlying networks at some level. And then we have, we can force attention. But it sounds like on psychedelics, the, one of the primary goals therapeutically is to really drill into one of these perceptual bubbles and expand that bubble. And the safety, it seems, is the safety, it's sort of like a permission to, to do that without worrying that something's gonna happen.

• 39:48Speaker 07

  Right, because, you know, I've had people there on the couch, um, yeah, I remember one lady said, this is probably thirteen, fourteen years ago, said, "Matt, tell me again, I can't die. Like, I feel like my heart is gonna rip through my chest." I mean, she was feeling her, and, and I should say, typically cardiovascular response is, is modest, the, the pulse and blood pressure go up somewhat. It can be dangerous for people if they're at severe heart risk and we do-

• 40:15Andrew D. Huberman?

  Are you monitoring this the whole time?

• 40:16Speaker 07

  We do, yeah, we do-

• 40:17Andrew D. Huberman?

  So they're plugged into a variety of devices?

• 40:19Speaker 07

  Yeah, so every half hour or so, we, we take their, on protocol, and we, you know, space it out a little further, further into the time course, but we take their blood pressure and their pulse. And if it goes over a certain level, we have a protocol, and we've had to do this only a few times, but physician comes in, gives them a little nitroglycerin under the tongue, uh, and, uh, you know, knocks the blood pressure down a little bit, doesn't affect the experience. So we have it all in place, even though they'd probably be fine out of an abundance of caution.

• 40:44Andrew D. Huberman?

  Sure.

• 40:45Speaker 07

  Um, but, but yeah, but someone can feel that, "My God, I'm gonna die." Like, I, I have never felt my heart beat like this before. And, like, the experience of the breath can be just, you know- Absolutely fantastic. And this sort of, and the breath is obviously interesting because it's this automatic, you know, control, but it could also be voluntary. So people get into a sense of like, my God, what if I, it sounds silly like a

• 41:14Andrew D. Huberman?

  What if I forget to breathe?

• 41:15Speaker 07

  Exactly. But people, that can be so compelling. And so one other, to get back to one of your questions, it's like, what do we do to kind of allow them to go further into these bubbles? It's like, one is, is wearing the eye shades. We don't call them blindfolds because that has a negative connotation like being kidnapped.

• 41:34Andrew D. Huberman?

  And they're probably seeing a lot in there anyway. So blind isn't the appropriate.

• 41:38Speaker 07

  Right, right. That's, I've never thought of it. These should be like inner sight shades.

• 41:42Andrew D. Huberman?

  But when you close the eyes, the, the levels of activity in the retina actually are maintained. It's sponta, it's just spontaneous activity.

• 41:50Speaker 07

  And it seems, and I'd be curious about your thoughts on this, I mean, but the way I describe it is that the, you know, the mind's eye, you know, this kind of loose term we use, can be on rocket boosters. So a lot of times, for some people, like a compound like psilocybin, for some people there's no perceptual effect. Like if they're looking at this room, it would pretty much look the same. Sometimes folks say, yeah, things seem a little bit brighter. Now, some people will say, oh my God, there's waves, that wall is waving and these curtains are, you know. On these compounds, people don't typically see pink elephants. You do actually get that in another class. I didn't mention the, the anticholinergics, sort of like atropine and scopolamine, those drugs.

• 42:34Speaker 07

  Those are, those are the true hallucinations where you thought you were having a conversation with someone who was never there.

• 42:39Andrew D. Huberman?

  Those that, we will definitely get to those. But when, the reason I kind of cringe is that, oh my, when you talked about those is that knowing a little bit about the pharmacology of acetylcholine, the, the idea of manipulating that system, to me, sounds very uncomfortable. Because like, the whole idea of, well, witches and flying, there was a whole history there, you know, hundreds of years ago, so-called witches, taking these agents and then thinking they were flying around on broomsticks and things of that sort. And, and there's a lot of mythology around the broomsticks, it's complicated. But, but that sounds very unpleasant. One thing I, about the serotonergic, let's just, for, with psilocybin.

• 43:23Andrew D. Huberman?

  So there's a pers- an expansion of a particular fairly narrow percept. It could be sound, could be an emotion, could be sadness, could be a historical event, or a fear of the future. And you've mentioned before that there's something to be learned in that experience.

• 43:40Speaker 07

  Yeah.

• 43:41Andrew D. Huberman?

  There's something about going into that experience in it, in an un- um, in an, in an undeterred way that allows somebody to bring something back into more standard reality.

• 43:55Speaker 07

  Yeah.

• 43:56Andrew D. Huberman?

  Given the huge variety of experiences that people have on psychedelics, given the huge variety of humans that are out there, but what are now very clear therapeutic effects in the realm of depression, what do you think is the value of going into this fairly restricted perceptual bubble, what we are calling letting go, or giving up control? Because if the experiences are many, but the value of what one exports from that experience is kind of similar across individuals, that raises all sorts of interesting questions. And this is not a philosophy discussion, we're talking about biology and psychology here.

• 44:35Speaker 07

  Yeah.

• 44:36Andrew D. Huberman?

  So, let's say I decide I'm gonna focus on the tip of my pen. I mean, in a psychedelic state, I could fall in love with this pen. I do happen to like these Pilot V5s and V7s very much, but I could feel real love

• 44:49Speaker 07

  Yeah.

• 44:49Andrew D. Huberman?

  for the pen.

• 44:50Speaker 07

  Yeah.

• 44:50Andrew D. Huberman?

  Right, that's not an unreasonable thing to expect on a psych- in a psychedelic journey.

• 44:54Speaker 07

  Right.

• 44:54Andrew D. Huberman?

  And in the context of your laboratory model, which I think is a great one, that experience would be just as valid as me going into the experience of some of the deep friction that I might have with a family member over my entire lifespan.

• 45:08Speaker 07

  Yeah.

• 45:08Andrew D. Huberman?

  And yet, the export from that, those two vastly different experiences, is one of feeling a better relationship to the world and to oneself.

• 45:18Speaker 07

  Right.

• 45:18Andrew D. Huberman?

  So what does this tell us about?

• 45:19Speaker 07

  How can the pen and the processing your childhood trauma both lead to?

• 45:23Andrew D. Huberman?

  Right.

• 45:24Speaker 07

  Yeah.

• 45:24Andrew D. Huberman?

  So what does this, I mean, at that level, it raises this question, like, how, first of all, how, why, I mean, or just what are your thoughts on that?

• 45:34Speaker 07

  So this is definitely in the, this is in the terrain we're figuring out, you know, so there's no, the educated speculation is the best I can provide, but I-

• 45:45Speaker 07

  I think the best, the most, I think the common denominator are persisting changes in self-representation.

• 45:55Andrew D. Huberman?

  Okay, tell me more about self-representation.

• 45:57Speaker 07

  That's the way one holds, the sense of self, the fundamental relationship of a person in the world. I mentioned earlier that these experiences seem to alter the models we hold of reality. And I think the self is the biggest model, that I am a thing that's separate from other things. And that's, I am defined by certain, I have a certain personality, and I'm a smoker that's having a hard time quitting, or I'm a depressed person that, you know, views myself as a failure, and all of these things, those are models too. And I think, I think that change in self-representation may be an endpoint for these different experiences.

• 46:38Speaker 07

  I mean, maybe the falling in love with the pen, the whole idea that you're, especially in contemplation afterwards, and obviously I'm speculating here, but the whole idea that you could have such a deep connection with this random, obviously random aspect of the universe, could potentially lead to this, you know, transformed understanding of the self, and like, the pen may be a proxy for the miracle of reality, in a way that relies nothing on, on no supernatural thinking. You know, you can be a hard atheist and take this, and ultimately, oh my god, like that, just like the pen, this is, you know, this is amazing, the fact that we exist, and so there could be an extrapolation chair.

• 47:22Speaker 07

  And you use the pen, but I think it sounds so similar to Aldous Huxley's classic description in The Doors of Perception of the chair and the drapes, like he took 500mg of mescaline, he was just like-

• 47:34Andrew D. Huberman?

  Is that a high dose of mescaline?

• 47:35Speaker 07

  Yeah, yeah. And that's, you know, that's a heroic dose, for sure. And he's just going off on the chair-iness of the chair, like this chair is exuding the quality of being a chair.

• 47:47Andrew D. Huberman?

  So this is this expansion of the perceptual bubble. A narrow, a narrow percept that then grows within the confines of that narrow percept.

• 47:57Speaker 07

  Yeah.

• 47:58Andrew D. Huberman?

  So sense of self is a very interesting phenomenon. And if we could dissect it a little bit. There's the somatic sense of self, so the ability to literally feel the self. In this process we call interoception. And then there's the, the, the title of the self, the I am blank.

• 48:15Speaker 07

  Yeah.

• 48:15Andrew D. Huberman?

  And I noticed you said that several times and it's intriguing to me. I have a, a good friend, I don't think I, I can or should mention his name, but he had a very long and successful career. Within one of the more elite teams and within the SEAL teams. And he, um, he's a fairly philosophical guy, um, also a very practical guy. Uh, but he has said many times, um, to me that the most powerful words in any language are I am. Because whatever follows that tends, if you repeat it enough, tends to have this, uh, kind of feedback effect on the, on how you are in the world. And it, at the first pass, it, it all, it sounded to me a little bit like, you know, kind of like internet psychology type thing.

• 48:59Andrew D. Huberman?

  Like the secret or something, which frankly, I'm just not particularly. Yeah, you know, so if you, you kind of like the whole fake it till you make it. Like I, I don't actually subscribe to any of that. But in dissecting that a little bit further with him, I, I came to realize that, um, that these words I am are very powerful. I don't think you reprogram your brain just by saying them. But how one defines themselves internally, not just to other people. But how one psychologically and by default in, uh, defines themselves, I think is a very powerful like. Um, and depressed people as well as happy people seem to define themselves in terms of these categories of emotional states. So I think it's, it's so interesting that.

• 49:42Andrew D. Huberman?

  Letting go and going into this perceptual bubble, which is facilitated by, obviously, a really wonderful team of therapists, but also the serotonergic agent,

• 49:51Speaker 07

  Yeah.

• 49:52Andrew D. Huberman?

  allows us to potentially reshape the perception of self. That's a tremendous feat of neuroplasticity.

• 50:00Speaker 07

  Right, and I think certainly more work needs to be done. You know, this is the horizon. And I should credit Chris Lethaby, a philosopher in Australia, who has a forthcoming book. It might be out right about now or soon, within the coming months. Psychedelics and Philosophy.

• 50:21Andrew D. Huberman?

  That's the title of the book?

• 50:22Speaker 07

  It's, it might be Psychedelic Philosophy. It's really close.

• 50:26Andrew D. Huberman?

  Chris Lethaby, we'll put a link to it.

• 50:28Speaker 07

  Right, and so his conclusion in this, it's a really great book, and he really plays with the idea. It's like psychedelic experiences come along with a lot of supernatural stuff, experience. It can certainly go along with that. But the idea is like, can these experiences, and including the therapeutic effects, be explained from a naturalist point of view? And his conclusion is that the changes in self-representation may be the commonality. Now, that could go along with plant spirits and the Buddha and chakras and whatever your model, you know, system, in Jesus, all of that. But it could also be completely devoid of any supernatural, any religious.

• 51:12Speaker 07

  And we do, in fact, see all, you know, all of these varieties. So I think there's something about this change in sense of self. There is, it seems to be something on the identity level, both with, I think of the work we did with cancer patients who had substantial depression, anxiety because of their cancer, and also our work with people trying to quit cigarette smoking. I mean, there's this real, there seems to be, when it really works, this change in how people view themselves, like smoking, like.

• 51:43Speaker 07

  Really stepping out of this model like I'm a smoker. It's tough to quit smoking cigarettes. I can't do it. I failed a bunch of times. I remember one participant during the session, but he held on to this afterwards said, my God, it's like, I can really just decide, like flicking off a bike. I can decide not to smoke. And it's, I call these duh experiences with psychedelics because people often, like in the cancer study, you say, I'm causing most of my own suffering. Like I can, I can follow my appointments. I can do everything, but I can still plan for the, I'm not getting outside, you know, in the sunshine. I'm not playing with my grandkids. I'm choosing to do that. And it's like, they told themselves that before and the smoker has told themselves a million times, I can choose.

• 52:28Speaker 07

  So it sounds, when it comes out of their mouths, and folks will say, this is part of the ineffability of a psychedelic experience. Folks say, I know this sounds like bullshit and this sounds like, but my God, I could just sigh. Like they're feeling this gravity of agency and which I think is interesting because regardless of the, the, you know, debates on the reality of free will, I think the philosophy of that, whether there's, it's ultimately free, free will, like pure agency, if that exists, which I'm skeptical of, or just the idea that clearly we have a sense of agency. There's something there, whether it's the sense of agency even, that is, the human being has.

• 53:10Speaker 07

  And that seems to be at times fundamentally like supercharged from a psychedelic experience. This idea like, I'm just going to make a decision. Like normally, like you tell a depressed person, like, don't, don't think of yourself that way. You're not a failure. Look at all the, it's just, yeah. It's like, and you can actually in one of these states have an experience where you realize like, my God, just like using MDMA to treat PTSD and we're going to be starting work with psilocybin to treat PTSD, someone could really reprocess their trauma in a way that like has lasting effects. And clearly there's probably something, you know, reconsolidation of those memories. They are, they are altered, you know, very consistent with what the, our understanding of the way memory works.

• 53:54Speaker 07

  So the whole idea, people can actually in, in a few hours have such a profound experience that they, they decide to make these changes in who they are and it sticks. There seems to be something like that.

• 54:08Andrew D. Huberman?

  And that's profound. I mean, I, I think. A few moments ago, I made some semi-disparaging statements about things like the secret and affirmations. And the reason I do that with a nod to the fact that the people who are putting those ideas forward are well-intentioned people is that the neural networks of the brain put language last. We tell stories, and stories are very powerful. But I think one of the most cruel aspects of the whole self-help literature and popular psychology is this idea that everything you say, your brain and body hear it.

• 54:50Andrew D. Huberman?

  That's actually a very unkind or even cruel thing for people who are depressed or anxious to hear. Because if they hear that and believe that, and I want to be clear, I don't think it's true, that they think that it's very hard to control thoughts. It's very hard to control thoughts. So if somebody says, "I can't," and then somebody says, "Well, no, every time you say you can't, your brain hears that and it reinforces it," that's a very treacherous place to live. And language is powerful, but neural networks, the brain, and the networks that underlie emotionality and perception and sense of self, they don't change in response to language. They change in response to experience.

• 55:33Speaker 07

  Yeah.

• 55:33Andrew D. Huberman?

  And just fundamentally, you need, there are some prerequisites. You need certain neuromodulators present, like serotonin or dopamine. You need those to be at sufficient levels. You don't need a drug necessarily do it. You could, you know, you give a kid a kitten or a puppy, their first kitten or puppy, and the levels of dopamine and serotonin, I've never measured them, but we can be pretty sure that they are higher than baseline.

• 55:56Speaker 07

  Uh huh.

• 55:56Andrew D. Huberman?

  And that experience will reshape them.

• 55:58Speaker 07

  Right, yeah.

• 55:59Andrew D. Huberman?

  Likewise with an adult in a certain circumstances. So I think, I'm fascinated by this idea that a somatic and a perceptual experience, but a real experience of the sort that you're describing, is what allows us to reshape our neural circuitry and to feel differently about ourselves. And I know there's been really tremendous success in many individuals of alleviating depression, of treating trauma with these different compounds. I wanted to step from the... The experience under the effects of the psychedelic. So the person there with your team, they go into this expanded perceptual bubble. If, if things go well, they're able to do that to a really deep degree.

• 56:44Andrew D. Huberman?

  Maybe it's the, the relive trauma. Maybe it's the beauty of the, their ability to connect to things in the world. Now I want to talk about the transition out of that state. And then the export into life. Because this is really where the power of psychedelic seems to be in the therapeutic sense. Is the ability to learn, truly learn from that experience so that the learning becomes the default. That one doesn't have to remind themselves, oh, I am, you know, they don't have to do an affirmation. I am a happy person. I am a happy, you know, I always think of Bart Simpson, like writing on the chalkboard. Right, didn't work for him, doesn't work for this other stuff too. But, so as they transition out of this state, I know that there's a kind of a heightened, there's a so-called peak.

• 57:23Andrew D. Huberman?

  Where everything seems to be kind of cascading in at such a level that, um, the person just, they can't really turn it off at that point. It would be challenging. Um, and then they start to exit the effects of the drug. Are those transition zones, are those valuable? Much like, is the transition between a dream and the waking state valuable? Because you're in a sort of mishmash of altered reality and new reality.

• 57:52Speaker 07

  Right.

• 57:53Andrew D. Huberman?

  What do you, what do you do to guide people through the, um, out, out the tunnel? As they exit the tunnel?

• 57:59Speaker 07

  And I have to say, like, this is where we need more experimentation. Um, really, the clinical model goes back to literally the night, late 1950s. And there's been virtually no experimentation on, let's say, you know, randomized people to, we're going to talk more during the latter half of the, of the session versus not. Versus we have them, you know, write an essay after their session versus not. Versus we have this amount of integration.

• 58:26Andrew D. Huberman?

  What's the follow-up in your studies? Are they, are they writing or talking as they're doing it?

• 58:31Speaker 07

  And it's called, you know, very loosey-goosey, you know, term, integration. But for us means, um,

• 58:38Speaker 07

  As they're coming back from the experience, it's sort of five, six hours in. You know, so this is the afternoon, they've been dosed around nine o'clock. So this is like four o'clock or so. Just some initial, tell us about the experience. Do you want to not unpacking it totally, but kind of initially just have a little bit discussion before they go home. So there's a little bit of that. But then that night, their homework is to write something. So it could be, you know, a few bullet points. It could be, you know, 20 pages and we, we get everything, you know, in that range. Um, but, you know, try not to be self critical. It's not great. It like, this is just to process and for a point of discussion the next day. So they write something, they come in the next day for a, a, a one to two hour, depending on the study, integration session.

• 59:22Speaker 07

  Basically just let's discuss your experience and depending on what study it's in, like what, you know, what might that mean for? You're dealing with cancer. What might that mean for your, your smoking, um, you know, or becoming a non smoker? So you encourage them to simply take it seriously. And I think this is again, is sort of one of the points that could be the antithesis of what some just kind of social users. Um, use, I mean, this was written about by, um, Houston, uh, Smith, the scholar of religion in terms of these mystical experiences that can happen from psychedelics. And how a lot of times the attribution to a drug effect is dismissed, like the, even if one has this, you know,

• 1:00:05Speaker 07

  this sense of being one with the universe and it totally like shakes their soul, so to speak. You know, but the next day their friends are like, oh dude, you were screwed up. Too much acid for you. Woo, you know, like man, next time you needed to have a few more beers to like bring that down. You know, like this sort of like, you know, social, you know, reinforcement for dismissing the experience. Oh God, you were talking out of your head, man. Like, you know, even if it's, you know, good natured, but it's this dismissal. It's not like.

• 1:00:36Speaker 07

  You know, what you wanna do, you know, is like, tell me more about that, you know, you were crying at one point, like, in talking about your mom. Let's talk about that. What was that like? Do you remember that?

• 1:00:46Andrew D. Huberman?

  Are you doing that follow-up? Or they're encouraged to do that in their own life with the various people in their life?

• 1:00:52Speaker 07

  Both. So we do that explicitly in the follow-up, where we have these discussions. And I, depending on what the situation is, you might encourage the person to kind of follow up. It's really, the basics of it is supportive therapy. It's non-structured. It's, you know, use all the, you know, reflective listening and the sort of the humanistic psychology, you know, unconditional positive regard for the person. But, but, you know, I think if, you know, if someone feels inclined to, you know, apologize to their, to their, you know, to their sibling about something, it's like, yeah, go ahead and call them up. When it, with something big, like a relationship change, I'd be like,

• 1:01:37Speaker 07

  sit on that two weeks. Don't make any big, don't end any relationship. Don't quit your job. Don't make any big.

• 1:01:43Andrew D. Huberman?

  Do you also tell them not to start any relationships?

• 1:01:48Speaker 07

  I don't remember that ever coming up.

• 1:01:50Andrew D. Huberman?

  Interesting. I'm not Joey. I was just wondering, you know, it's, but it makes sense why.

• 1:01:54Speaker 07

  Like if they're dating and they're thinking like, ah, it might be time to take it to the next level. Should I ask this girl to marry me? If it did come up, I would say there too. Um, why don't you sit on that a week or two?

• 1:02:05Andrew D. Huberman?

  Yeah, don't get a puppy.

• 1:02:05Speaker 07

  And let your sober mind.

• 1:02:06Andrew D. Huberman?

  Don't get a puppy. Certainly don't get four puppies until you're... I have a question about flashbacks.

• 1:02:14Speaker 07

  Uh huh.

• 1:02:15Andrew D. Huberman?

  You know, one of the kind of things you hear is, you know, flashbacks and that, that people, do people get flashbacks? And if so, what is the basis of flashbacks? The, um, the on-the-street lore about this is that somehow, some of the compound gets stored in body fat tissues and then released later. Like, is that complete nonsense?

• 1:02:37Speaker 07

  No evidence for that. So probably complete nonsense.

• 1:02:41Andrew D. Huberman?

  Flashbacks are nonsense, or the storage in body fat is complete nonsense?

• 1:02:44Speaker 07

  The storage in body fat. So to answer whether flashbacks are complete nonsense, we have to define it. So I really think these are multiple constructs that are going. It's not the same thing that fall under that term. There is a phenomenon that, that appears real that's called hallucinogen persisting perceptual disorder. It's in the DSM. A certain number of people, a very small number of people, uh, you know, percentage wise, who have used psychedelics, will have these persisting perceptual disorders, like they'll see halos around things, they'll see some trails, like, you know, like the afterimages following a, an object in motion, um, uh, they'll see distortions in color, and it'll

• 1:03:26Speaker 07

  be like anything else, that's a, a disorder in the DSM, it has to be clinically distressing, and it has to be persisting over some, uh, number of, of months, and, and so, very rare, very mysterious, some of the keys to that are, amazingly, it's never been seen in the thousands of participants, either from the older era, from the late 50s to the early 70s, the people in psychedelic studies with LSD, psilocybin, mescaline, and it's never been seen in the modern era, again, now with thousands of participants at a number of centers like ours, um, throughout the world. So, it seems to be something that is, for some reason, happening in illicit use.

• 1:04:08Speaker 07

  So, that, that brings in, okay, is there polypharmacology? Right. You know, like, cause you're drinking during any- Did you take what you thought you'd take? Yeah, what's the dose, is, what's the purity? But then also, what I think is actually even more so than that, what's likely going on is some sort of very rare neurological susceptibility. There is one paper that, um, is a case series of individuals reporting these symptoms, and they didn't limit it to the, to just people who had had, um, hallucinogen history. And the amazing thing about this is that, uh, a number of people seem to have straight up HPPD diagnosis- What is HPPD? Uh, hallucinogen persisting perceptual disorder, who have never taken a psychedelic.

• 1:04:50Speaker 07

  So, it's often prompted by, um, alcohol, benzodiazepines, cannabis, um, even tobacco. And, and I believe in one individual, no lifetime history of any, it wasn't preceded by any of those, uh, you know, substance, um, uses. So, I think it's-

• 1:05:13Speaker 07

  I think of it like the precipitation exacerbation of psychotic disorders. We, it seems pretty clear through observation that some people with, with either predisposition or active psychotic disease, that this can destabilize them. Uh, psychedelic, the same way that a life experience can destabilize those person more easily. I think of it like that there's probably some pretty rare neurological susceptibility. We have tended going, this goes back to the eighties. You know, clinical practice, it ended up in the DSM focused on hallucinogen because I, I relate it to the, the psychology of xenophobia. It's always the weird other thing that gets the attribution. You don't attribute to the thing like, oh yeah, did you smoke cigarettes? Did you drink?

• 1:05:55Speaker 07

  It's like, well, yeah, but I see lots of people drinking and not ending up with this. Like you take a, a crazy like drug and you can get pe- people to believe all sorts of crazy stuff. The biggest example of that is the, the, the cathinone derivatives, so-called bath salts. And if you remember several years back.

• 1:06:13Andrew D. Huberman?

  Oh yeah.

• 1:06:13Speaker 07

  The guy in Florida that, that ate the other guy's face. There was a homeless guy that like literally ate part of someone's face off. Like, yeah.

• 1:06:21Andrew D. Huberman?

  While the person was alive.

• 1:06:23Speaker 07

  While the person was alive and all it took was one Sheriff Steppity to say, well, I don't know, but I bet it was some of that bath salt stuff that's been going on. The only thing.

• 1:06:33Andrew D. Huberman?

  What, what was it? Was it?

• 1:06:35Speaker 07

  The only thing in his system.

• 1:06:36Andrew D. Huberman?

  Maybe we could set the record straight for people. What, what was this? Why would he say bath salts? And was it bath salts?

• 1:06:42Speaker 07

  It wasn't. And, and so the only thing in his tox was cannabis, which we all know typically people don't eat people's faces off after they get.

• 1:06:51Andrew D. Huberman?

  Makes you hungrier, but not that.

• 1:06:52Speaker 07

  Right. Right. So it's just an example of the xenophobia. Like today, if you get on Google images and look up, you know, bath salts, one of the most common, you know, images you'll see is this poor guy's face being eaten off. So we're just so ready to latch on, just like the people of another culture that we don't know of. It's, it's, it's very easy to assign attribution to a class that you're very unfamiliar with. So I think they, the psychedelics got that attribution with this very rare neurological susceptibility, the way that alcohol didn't. So I think it's not specific to psychedelics, but we don't really know. We need, but we, we'd look at it and our research have never seen an example of it. But flashbacks can mean a number of other things.

• 1:07:38Speaker 07

  I think the most common thing people experience is what we call state-dependent learning. It's returning yourself to a similar context can bring back the same thoughts and emotions as the experience. So, you know, someone used mushrooms a week ago, now they do something like they smoke some cannabis, or they take a warm bath, or they're simply like relaxed, it seems to come out of the blue, and all of a sudden, or they follow a thought trail that takes them, that reminds them of their, and they find themselves in that same experience again. I think that's more state-dependent learning. It's not the distressing component that is in, and it's typically not perceptual.

• 1:08:22Speaker 07

  And then, another class are just sort of perceptual anomalies within a day or two following the experience, which is not HPPD. Most people have joked that this is a free trip, like you might see a few trails or halos the day afterwards. It doesn't last longer than that, and it doesn't screw you up, it's kind of fun, like, oh yeah, I'm still seeing some trip, most people will say. So, it could mean any of those things.

• 1:08:49Andrew D. Huberman?

  Got it.

• 1:08:50Speaker 07

  So flashback is, yeah.

• 1:08:51Andrew D. Huberman?

  Interesting. No, I appreciate you clarifying that. I mean, one very common misconception about neuroplasticity is that it's an event, and it's not an event, it's a process. And we have no understanding of the duration of that process. However, the experience of any drug or any life experience, right, even if it's a trauma or a wonderful experience, or psychedelic experience, doesn't matter, sets in motion a series of dominos that fall, and it's the falling of those dominos that we call neuroplasticity. I mean, the reshaping of neural circuits could take years. We don't know. It's the trigger, and then there's the actual change.

• 1:09:32Andrew D. Huberman?

  And so I think that some of what you described could be literally the reordering of circuitry that in some individuals might extend longer than others. And there is one phenomenon that I've been told people experience, and I'm wondering whether or not any of the patients you've worked with, or people in your trials have reported this. I've never done ayahuasca. Which I'm assuming has some overlap with the serotonin system, probably hits a variety of

• 1:10:02Speaker 07

  So it's DMC, the active, yeah, it's orally active, MAO inhibitors that allow the DMT to be orally.

• 1:10:08Andrew D. Huberman?

  Right, I should have, I should have recalled that, absolutely. Well, I've never done it, but a number of people I know that have done ayahuasca, as well as people I know who have done MDMA, report an increased sense of what are sometimes called ASMR, or these autonomic sensory meridian reflexes, which is, and it's interesting, a lot of people have these naturally and they hide these, these are, it's actually something that many people keep hidden to themselves. I'll just ask you if you can do it. So, some people are able to pass a, like a shiver down their spine or up their spine consciously, you know, like you can kind of, like I'm able to actually pass a shiver up my spine. I actually learned how to do this when I was a kid on a hot day, I was standing on a

• 1:10:51Andrew D. Huberman?

  field in sports camp, and I was like, it's really hot here, and I could actually create like a cooling, cooled perception. Some people, I told someone this once, and then this led to a discussion of, oh, I can do it, but I always hid that from people, because it's actually somewhat pleasurable. And this is a well-known phenomenon, ASMR. And some people I know who have taken MDMA therapeutically or ayahuasca, will report that they feel great relief from this, they can generate these autonomic reflexes through their body more readily. Probably, I'm guessing, because they were able to tune into a kind of deeper sense of somatic self. Now, on the internet, ASMR, if you look it up, it's a little bit like the bath salt

• 1:11:33Andrew D. Huberman?

  thing, but in the other direction, like, there were people that pay, let's just say there are accounts on YouTube that have many, many millions of viewers of people that will whisper to them about, like, for instance, there's a, people that will go listen to It seems to be women in particular whispering about like car mechanics or something or about or scratching. So there are certain sounds will do this whispering, tapping, finger tapping. And people experience immense pleasure from it. It's not really sexual pleasure, but it's this kind of deep core of the body. It's the autonomic nervous system down the core of the spine.

• 1:12:09Speaker 07

  Probably what a certain number of people would call Kundalini, which is another one scientifically.

• 1:12:14Andrew D. Huberman?

  That's right. And people who do long duration Kundalini breathing sessions, many of them will report later feeling as if they, their perception of self is outside of their head. That they're rut, that they're literally walk, it's very uncomfortable for them. That they feel like they're walking around with their sense of self extended beyond the body. And this is a neural, this is a clinically described neurologic phenomenon.

• 1:12:37Speaker 07

  Have any studies been done? I would imagine that person might actually like, would they duck?

• 1:12:41Andrew D. Huberman?

  Oh, what?

• 1:12:42Speaker 07

  Like, that would be an interesting experience.

• 1:12:44Andrew D. Huberman?

  That would be the kind of thing my lab would want to get into. That's right.

• 1:12:46Speaker 07

  Yeah, their body could clear, but their

• 1:12:47Andrew D. Huberman?

  Right.

• 1:12:48Speaker 07

  Projection wouldn't.

• 1:12:49Andrew D. Huberman?

  Yeah, the sense of self, I mean, there's a, there's a well-known phenomenon. It's very, in a few individuals, very sad, where people actually avidly seek out amputation of their limbs because their limbs, they feel, don't belong to their body.

• 1:13:02Speaker 07

  Oh, yeah.

• 1:13:02Andrew D. Huberman?

  This is a very sad and fortunately very rare, but also very sad condition. Anyway, I think that the, the, the core of this conversation that we're, we're drilling into is this notion of, of reordering the self. And it's, and it's a relief to me to know that flashbacks are not something that is kind of, forgive the term, baked in to the, to the psychedelic experience. And I suppose that's a good segue to ask about other sorts of drugs. I, having said baked in, the temptation is to go to marijuana, cannabis. But, but if we, if we could, I'd like to just ask about some of the more dopaminergic compounds. In particular MDMA.

• 1:13:42Speaker 07

  Yeah.

• 1:13:43Andrew D. Huberman?

  My understanding is that MDMA is a purely synthetic compound, that you're not going to find MDMA in nature.

• 1:13:51Speaker 07

  So far.

• 1:13:52Andrew D. Huberman?

  So far.

• 1:13:53Speaker 07

  DMT was first synthesized in the lab and then we thought it didn't exist in nature. And then like Richard Schultes found it like everywhere in South America. So who knows, a plant out there might be making MDMA, but as far as we know now, no.

• 1:14:07Andrew D. Huberman?

  Right. And we'll talk about DMT and its sources within the body. But MDMA could exist elsewhere, but has been synthesized. And my understanding is that MDMA Leads to very robust increases in both dopamine and serotonin simultaneously, which from a neural networks perspective is a very unusual situation.

• 1:14:31Speaker 07

  Mm hmm.

• 1:14:31Andrew D. Huberman?

  Right? Normally, because dopamine puts us in this exteroceptive, looking outside ourselves, seeking things in the world beyond the skin, our own skin, and dopamine, excuse me, serotonin tends to focus us inward. Those are almost mutually exclusive kind of neurochemical states, although they're always at different levels. So why would it be that having this increased dopamine and increased serotonin would provide an experience that is beneficial? And how do you, to the extent that you can describe it, how do you think that experience differs from the sorts of experiences that people have on psilocybin or more serotonergic agents? Just broadly speaking?

• 1:15:12Speaker 07

  Yeah, yeah. In terms of that, that balance, in terms of the effects generally on serotonin and dopamine, I can only speculate, you know, like, sort of, is that dopaminergic component necessary for, let's say, we know that the amygdala is less reactive during, you know, under acute effects, and that may play a role in, there's less sort of control from the amygdala in terms of like one's experience of memory. So it may be part of this sort of reprocessing, this reconsolidation of these memories in a different way, where the amygdala is not like going crazy, saying freak out, like, you know, fight or flight.

• 1:15:54Andrew D. Huberman?

  Well, and I should have said, it seems like MDMA is being used clinically, anyway, mainly for trauma, not just for depression.

• 1:16:03Speaker 07

  Although, part of that, we really don't know. And maybe that MDMA is great for depression and some of these other, and it may be that, and I'm going to be looking at this soon, that psilocybin is great for treating PTSD. A lot of underground therapists say that, underground psychedelic therapists. So we don't really know yet.

• 1:16:22Andrew D. Huberman?

  What do you mean by underground? Oh, because they're doing it.

• 1:16:24Speaker 07

  People doing illegal, you know, but more like, you know, a professional therapist would, it's just illegal. And this is a kind of a growing thing. So we don't really know which it. It speculating, but it may be that MDMA for a broader number of people is better for for trauma because the chances of having an extremely challenging experience, what I call the bad trip, like really freaking out, is much lower with MDMA. People can have bad trips, but they're of a different nature. It's not, it's not sort of like freaking out because all of reality is sort of shattering and it's less of this, it can take so many

• 1:17:08Speaker 07

  forms with the classic psychedelics, but like typically you'll hear something like, I didn't know it was gonna be like this, no matter how hard you tried to prepare them, that like this is like, get me off this.

• 1:17:23Andrew D. Huberman?

  You're talking LSD or psilocybin?

• 1:17:24Speaker 07

  LSD, psilocybin, ayahuasca. Yeah, yeah. And, and just this sense of like, I'm going insane. This is so far beyond anything I've ever experienced and it's scaring the shit out of me. I don't have a toehold on anything, even that I exist as, as, as, as an entity. And that can be really, I think frankly, experientially, that's kind of the gateway to both the transcendental mystical experiences, the, the, the sense of, of unity with all things, which we know, our data suggests is related to long-term positive outcomes.

• 1:18:01Andrew D. Huberman?

  Wait, I want to make sure I understand. So you're saying the bad trip can be related to the transcendental experience?

• 1:18:06Speaker 07

  Right. I think those are both speculating, but you, you have to pass through this sort of like, you know, reality shattering, including your sense of self. And one can handle that in one of two ways. You can either completely surrender to it, or you can try to hang on. And if you try to hang on, it's going to be more like a, a bad trip. So again, I wish there was more and hopefully there will be more experimentation. There's a lot going on here in the black box in terms of the operant behavior of how you are, you know, within yourself, choosing to handle, like letting go, you know, and eventually we'll be able to see this in real time with brain imaging. Ah, there they are surrendering to the psychedelic experience. Here they are trying to hold on, but we're, we're not there

• 1:18:51Speaker 07

  yet. But I think it's a good, through clinical observation seems pretty clear that something like that is going on. And certain drugs like DMT, smoked DMT can be so strong. The reason I, I think that can be so. Extraordinary you can compare to the others because it like forces people like there is no choice to hang out in it.

• 1:19:09Andrew D. Huberman?

  I've never done it. I was told that DMT is like a high-speed locomotive into the psychedelic experience and out of the psychedelic experience.

• 1:19:17Speaker 07

  Yeah.

• 1:19:17Andrew D. Huberman?

  And there's no ability to hold on to the self while you're in the the kind of peak phase. Is that correct?

• 1:19:23Speaker 07

  A lot of people say that, but some Terrence McKenna, who is kind of the classic bard on DMT effects, he would say the sense of self wasn't intact, but everything else, the sensorium and what you navigated, what you oriented towards, everything else changed, basically. But it's hard to, when everything's changing, it's hard to say like, what is the self that's changing? What is the rest of the world?

• 1:19:47Andrew D. Huberman?

  Well, and language is is totally deficient to describe experience anyway, much less on a psychedelic. What is McKenna's background? Like, what is his qualification for being this, as you referred, this bard of of DMT?

• 1:20:01Speaker 07

  So, and we're talking about Terrence, and there's also the brother Dennis, whom I know, who's who's

• 1:20:07Andrew D. Huberman?

  Can only imagine what Thanksgiving dinner is like at their house.

• 1:20:10Speaker 07

  Terrence passed away years, a couple decades ago now. But he's sort of the one who's known as being a bard, and you can find hundreds, if not thousands of hours of him on the lecture circuit in the 80s and 90s on YouTube. But his background was really, oh, gosh, I don't recall what his college degree was in. But he basically, when he was like 19, he traveled to South America and and actually on the initial trip with his his brother, who was even younger than him, with some other friends and just in in search for a DMT snuff that they had read about from in the Harvard archives from the work of Schultes,

• 1:20:50Speaker 07

  from a generation before. But they had discovered all of these mushrooms growing that down there, the psilocybin mushrooms, what they recognized and just took a lot of mushrooms and and

• 1:21:04Andrew D. Huberman?

  And talked about it.

• 1:21:05Speaker 07

  Talked about it. Terrence was basically a very intelligent, very well-read in in literature and culture person that could be. He was sort of the the next generation's Tim Leary, someone who could really speak.

• 1:21:19Speaker 07

  Get a little closer to the magnitude of what the psychedelic experience was like for people. And he served, like Leary, somewhat of an advocate. I mean, he would tell people, folks, you could see, you know, the equivalent of a UFO landing on the White House lawn. Like, it's right there. It'll take five minutes. It'll shake everything in your reality. You know, he would sort of goad people into doing it.

• 1:21:43Andrew D. Huberman?

  Well, certainly, science and clinical medicine are just but two lenses with which to explore these things in life. But what part of the reason I ask is, I feel like, you know, in the world of health and fitness,

• 1:22:00Andrew D. Huberman?

  you have this very extreme condition of like Arnold Schwarzenegger's and bodybuilders who have like 2% body fat. And they look like, to most people, they look kind of freakish, especially now, right?

• 1:22:11Speaker 07

  Oh, especially now.

• 1:22:12Andrew D. Huberman?

  Especially now.

• 1:22:13Speaker 07

  Yeah.

• 1:22:13Andrew D. Huberman?

  And yeah.

• 1:22:14Speaker 07

  Made Arnold look like regular.

• 1:22:16Andrew D. Huberman?

  Exactly.

• 1:22:17Speaker 07

  Back in his day, yeah.

• 1:22:18Andrew D. Huberman?

  Yeah, and you have contortionists who can put themselves into a small box and wrap themselves into a pretzel. But from those two very extreme subculture practices, that, I don't know anything about contortionism really, but, except that they get really bendy, that, but, it's a community that included lifestyle practices and nutritional practices and then drug practices. From those very extreme subcultures, there's been an export, which is that, you know, weight training is healthy, right? The general public has done that, or that yoga is healthy. So contortionism to yoga, et cetera. And I feel like a similar thing is happening in the realm of psychedelics, where it was Leary and Huxley.

• 1:23:03Andrew D. Huberman?

  I mean, I, like, I'm from the Bay Area. I'm not far from the Menlo Park VA, where one flew over the cuckoos, is basically based on, right? Ken Kezzi and those guys, and the... You know, there has been an attempt at creating this movement toward openness about psychedelics and their positive effects. This has happened before. The difference is that now there are people like you inside the walls of the university, you're publishing peer-reviewed studies and things of that sort. The reason I asked about McKenna was, you know, it seems like McKenna and his brother are but, you know, just two of many people, Michael Pollan, et cetera, who have no real formal training in biology or psychology.

• 1:23:47Andrew D. Huberman?

  The other guys who were at universities lost their jobs. They were actually removed from places like Harvard and other universities for their kind of cavalier explorations, right? And now things are kind of returning. So in the same way that bodybuilding led to weight training in every corner gym, you know, men, women, and children. And contortionism is one extreme, but people generally think that yoga is a pretty healthy practice, right? There, these are matter of degrees, right? And now here you are inside the walls of a very highly respected university, Johns Hopkins. You're on the medical school side of the undergrad, so in the med school, which is, you know, a serious health institution.

• 1:24:34Andrew D. Huberman?

  You know, the question is to me, you know, what are the valuable exports, right? And where does the extreme lie? I mean, clearly, there's a problem with tinkering with reality through pharmacology. And there's a benefit, it sounds like, to tinkering with reality through pharmacology. And what's so striking to me is this is the elements of atypical experience, atypical representation of the self. So for the average person, right, or for kids that are hearing this, kids that are in their teens, right? What are the, I want to talk about what are the dangers of psychedelics?

• 1:25:19Andrew D. Huberman?

  This is something you don't hear a lot about these days, and it's not because I'm anti-psychiatrist at all, but what are the dangers, right? If a kid or adult has a predisposition toward, let's say,

• 1:25:32Andrew D. Huberman?

  Psychotic thinking, right? Or auditory hallucinations?

• 1:25:36Speaker 07

  Yeah.

• 1:25:38Andrew D. Huberman?

  Whereas on the Asperger's side of the autism spectrum, is there an increased risk of bringing the mind into these states? Because it sounds like a very labile situation. So could we talk a little bit about that? And are there classes of these different drugs, whether it be MDMA, LSD, or DMT, that you think are particularly sharp blades and therefore need to be wielded particularly carefully?

• 1:26:03Speaker 07

  Yeah, so these can be profoundly destabilizing experiences and ones that ideally are had in a safe container, you know, sort of where someone... What are the relevant dangers and what can we do to mitigate those? So there's two biggies. One, and I've already mentioned, it's people with very severe psychiatric illness, not depression, not anxiety. I'm talking about psychotic disorders like schizophrenia or mania as part of bipolar disorder. So and diagnostically, this has shifted.

• 1:26:47Speaker 07

  So it's a little hard to say how many people today with bipolar would have been labeled as schizophrenia back in the 60s when some of this early research or just clinical observation was done. So it seems very clear that folks with a predisposition or active disease, they could be destabilized. And so some of the cases that we know of, I always think of Sid Barrett, the first singer of Pink Floyd.

• 1:27:12Speaker 07

  Seems pretty clear, although I think the family...

• 1:27:14Andrew D. Huberman?

  I don't know what happened there. I should be... Sorry, Pink Floyd fans. I've never... The songs are just really long.

• 1:27:19Speaker 07

  Yeah, you're more of a punk guy, right?

• 1:27:21Andrew D. Huberman?

  Yeah.

• 1:27:23Speaker 07

  So I've got my foot in a lot of worlds, definitely in part in the Floyd world. But he basically went crazy early on. He... It seemed... I don't think his family ever admitted it, but he developed schizophrenia. Classic pattern. And he was doing a lot of LSD. But... You know, like a lot of these cases, it looked like he was showing all of the signs of, you know, some hints of that he had that susceptibility before. And often, this is hard to disentangle what causes what, because when do people typically, not always, but develop, when's the modal period for first break?

• 1:28:06Speaker 07

  It's adolescence, early adulthood, yeah. And when do people start playing with drugs? Same exact time period. So it can be hard to disentangle, but it seems pretty clear. Now, I should also say, there are cases of folks with schizophrenia that say psychedelics have helped them. There's anecdotes for everything, though.

• 1:28:25Andrew D. Huberman?

  Do the people around those schizophrenics say it's helped them?

• 1:28:27Speaker 07

  I don't know.

• 1:28:27Andrew D. Huberman?

  Because when schizophrenics say things, you have to...

• 1:28:30Speaker 07

  Yeah, you have to weigh it.

• 1:28:31Andrew D. Huberman?

  With all due compassion and respect for schizophrenia, it's a disorder of thinking. So if they're saying it helped them...

• 1:28:37Speaker 07

  Yeah, can you trust them? Yeah. I wouldn't be surprised if there was some kernel of truth in some cases, but they're just so... It seems very clear that the other side is there, too, and that there ever is a therapeutic potential there for those disorders, that that shouldn't be the first thing on our list. We need to learn a lot more because of the level of risk before we start, you know, doing research to see if, you know, psilocybin can help with schizophrenia. Like, I don't think that... That may never be the case, but even if it is, you'd have to be even more cautious and figure some more things out first with some of these other disorders.

• 1:29:14Andrew D. Huberman?

  What about bipolar? Bipolar disorder, can it be exacerbated by these...

• 1:29:18Speaker 07

  Yeah, and it's... It may be that, that, that sort of the manifestation of people having prolonged psychiatric issues after a psychedelic experience, as atypical as that is, when that happens, it may be that's... That might be more like a manic episode than a psychotic episode, and that can be a blurry line. And it's...

• 1:29:44Speaker 07

  The folklore is that, you know, people go on a trip and they never come back. That's clearly not the case because, you know, the drug has metabolized like for anyone else and the next day there's not, you know, there's virtually nothing in their system.

• 1:29:54Andrew D. Huberman?

  But it reshapes circuitry, I mean.

• 1:29:56Speaker 07

  Right, and there's still, and I, I really do think, you know, much like the positive, you know, long-term effects that, you know, this class of problems is related to like the, to the experience and the destabilization that can happen from that, from that experience if it's not in that, in the right container. And again, like, these people are susceptible to, you know, some people with that psychotic predisposition, they lucky to be born to a great family, stable environment, they maybe never have a full break, or the one that they have is not nearly as bad as what, you know, someone that is, who's homeless and is coming from all kinds of early childhood

• 1:30:39Speaker 07

  trauma, like, the disease is probably gonna be far worse, you know, so, you know, the, having a psychedelic experience is like one of those destabilizing experiences, you know, so, now fortunately, it's really easy to identify those people, and we even, you know, err on the side of extreme caution by eliminating people with like, say, a first-degree relative, in some studies even a second-degree relative. Given the heritability, there's some increased chance if your brother or your, yeah, so, so in an abundance of caution, even eliminating, I think eventually if it's approved for use, FDA use, that we could dial back on that as we learn more, I think it's, again,

• 1:31:21Speaker 07

  over, overly cautious, which is probably the appropriate.

• 1:31:25Andrew D. Huberman?

  But you're doing it early-stage clinical trials.

• 1:31:26Speaker 07

  Yeah, it's the appropriate place to start at this point in time, but, you know, if you, you know, give a SKID or another structured psychiatric interview with a clinician, sitting down with this person for a few hours to delve into their history, and, like, you can very reliably determine that this person. Has either, you know, a psychotic disorder or bipolar disorder or a strong predisposition. So that's, you know, that you can screen for that and that's how you address that. The far more likely danger is the bad trip. Anyone can have this. The most psychologically healthy person in the world, probably. You jack the dose high enough and especially in a less than an ideal environment, you can have a bad trip. You even get it in an ideal environment like ours at a high dose of around 30mg of psilocybin.

• 1:32:11Speaker 07

  After, you know, the best preparation we can provide, about a third of people will say, essentially, at some point, they have a bad trip, you know.

• 1:32:19Andrew D. Huberman?

  At some point within the entire journey.

• 1:32:21Speaker 07

  Right. Now, they could have one of the most beautiful experiences of their life, sometimes, like, a couple of minutes later.

• 1:32:27Andrew D. Huberman?

  Right.

• 1:32:27Speaker 07

  But at some point, they had a sense of strong anxiety, fear, losing their mind, feeling trapped, something like that. Now, typically, when people have that, you know, when they're just taking on their own, like a lot of things, they're fine. They get through it, you know. They're more likely to be better off if they're not having to navigate the streets of Manhattan, you know, and if they're with, you know, other people, with friends, better, that those friends aren't also dealing with their own psychedelic experience, but probably having some friend of any type, whatever on there is better than having nothing. So, very dependent on context. And so, the tough thing here that, in conveying to the public is that

• 1:33:11Speaker 07

  a lot of folks will say, "Man, I've taken psychedelics hundreds of times, and this is like you're fear mongering and, you know, there's no, you know, you're exaggerating the danger there." So I want to say, it is atypical. But sometimes, and I have a file folder that grows larger every year of these cases, either in the medical literature or from the news, of people that freak out on a psychedelic and they get hurt or they die. They run into traffic, they fall from a height, whether they thought they could fly or whether they just felt like you can do when you're drunk or you're intoxicated on any substance. Sometimes that's unclear. Or...

• 1:33:54Speaker 07

  Gosh, one of the craziest cases was a kid, like an 18-year-old or so in Oregon several years back that just, he even wrote about, "I want to take the biggest," he had done mushrooms before, "I want to take a heroic dose, the biggest dose I've ever taken." He ended up just totally out of it, ended up in a neighbor's house. He was just totally disoriented, disconnected from reality, and the cops ended up killing him. And it was just tragic. Obviously, an overuse of force in that case, because he was actually naked at the time, this naked, like, 120-pound, I think, as a recalled kid that ended up dying.

• 1:34:26Andrew D. Huberman?

  Well, it's analogous to the, you know, the reason I use the examples of like bodybuilding culture. I mean, people there have taken excesses of amounts of anabolic and diuretics and died. Then the contortionist culture, people have put themselves in little plexiglass boxes to do, you know, at the extremes, you're going to get deaths. And at the extremes, and one of the extremes is the sheer number of people with different biological makeups taking the same drug. And so you can create extremes through numbers, you can create extremes through dosage, right? It seems. Well, this is why I'm such a fan of the fact that people like yourself are doing clinical trials inside the walls of universities,

• 1:35:08Andrew D. Huberman?

  not because I think that psychedelics only have utility in those environments, but because it's so important toward creating their transition to legality and to understand what legality means for a compound like this, right?

• 1:35:24Speaker 07

  Right, what model?

• 1:35:25Andrew D. Huberman?

  Right. I mean, again, we'll stay with the anabolic steroids. There's now testosterone and estrogen replacement therapy. Hormone replacement therapy is a common medically-approved practice, but that's vastly different than people taking their own stuff for diet or deciding how much they need to take, right? Like we said, there's yoga, and then there's contortionism in a plexiglass box, and, you know, thinking of Houdini or something. So there, these are a matter of degrees. Speaking of dosage, I definitely want to ask you about microdose versus standard or macrodose.

• 1:35:58Andrew D. Huberman?

  Tell me, tell me that I'm wrong, but I'm always a little bit, um, I sort of a little, uh, I'm micro cynical, uh, if you will, about this term microdose. And the reason is that many people that I know who talk about microdosing are taking dosages of compounds that work at Mike, that are very powerful at microgram levels. So the word micro, I think can be a little bit confusing to people because microdose implies less than something. It's a mini dose, right? And yet some of these compounds were, are tremendously powerful at microgram concentrations.

• 1:36:41Andrew D. Huberman?

  So what it constitutes a microdose and what is the value of so-called microdosing, if any? And how does it differ from standard or what I can only assume is called macrodosing?

• 1:36:55Speaker 07

  Yeah. And so LSD would be the, the, the prototypical example of that super potent.

• 1:37:00Andrew D. Huberman?

  Yeah. How much might, what, what size dosage of, of LSD will lead to hallucinations and kind of standards?

• 1:37:07Speaker 07

  So sort of the entry point for psychedelic type effects, which may not involve hallucination. Actually, most classic psychedelics don't lead to true hallucinations as defined in psychiatry of, you know, thinking you're talking to the person that's out there seeing the pink elephant.

• 1:37:22Andrew D. Huberman?

  No, it's more like tracers and things like that.

• 1:37:25Speaker 07

  Right.

• 1:37:26Andrew D. Huberman?

  Perceptual blending.

• 1:37:27Speaker 07

  And some people never get that, even at a very high dose. So I think more broadly in terms of the psychedelic effects, which isn't just perceptual, unless we get into the level of, as you were alluding to earlier, a broader definition of perception, like one's models of the world, the model of the self, you can, you can consider all of that perception in terms of, you know, truly not sensation, but the perception, the construction of, of putting together reality. So, um, yeah, yeah, yeah. So do psychedelic effects are, are typically considered to start for LSD around a hundred micrograms? So a, a tenth of a milligram is a hundred micrograms.

• 1:38:05Andrew D. Huberman?

  Right. So someone taking a hundred micrograms of LSD, they, on this, nowadays, people might mistakenly refer to that as a microdose because it's micrograms, but that's actually a macrodose of LSD.

• 1:38:17Speaker 07

  Right. They might, and that's one of the most common mistakes or situations that people get into with microdosing is they intended to be a microdose, but it ends up being a full-blown. You know, dose. Now, people do, when they're working with LSD and they're microdosing, they'll shoot for something like, say, ten milligrams, you know, something in that range, ten, twenty milligrams of LSD. So, you know, a tenth, a fifth, something of kind of your entry-level psychedelic dose. People's ability on the street to do this, and I say the street as if they're on the corner, but anyway, like, outside of the medical profession to do this, like, varies as you can imagine.

• 1:38:55Andrew D. Huberman?

  And they're not measuring purity or malarity or things like that, typically.

• 1:38:58Speaker 07

  And there's ways to do it. So even if you don't ultimately know the dose that's in, like, the blotter paper of acid, one could at least get a sense of, like, yeah, having one of those tabs is, one of those hits is, is a psychedelic experience. They could do something like, put it in water, it's a hundred percent aqueous soluble, you could, you know, make sure it all gets into solution, and then volumetrically measure, it's gonna be homogeneously distributed, so you can, you take one tenth of that volume of water after it's fully dissolved, you know, that whatever you started with, you're gonna have a tenth of that dose. So the people that are more sophisticated will do things like that. And when they're working with mushrooms, they'll, they'll grow a bunch of mushrooms, and then they'll, say, put it in a coffee grinder. I'm not telling people to do this, by the way, I'm just describing, so don't do this at home, but like, grind

• 1:39:43Speaker 07

  it all up so it's homogeneous, because you can have, like, you know, sort of taking, you know, two caps and a stem, hey, this two caps and the stem that this buddy takes is, has a different potency than this two caps and a stem that the other buddy takes. So, people that are kind of in the know will, will grind it all up into a homogeneous powder, and they'll pack it into whatever size capsule, and they'll know that, and again, even if they don't have, sometimes they might have a buddy that'll sneak it into the HPLC at their, at their job or whatever, if they have.

• 1:40:11Andrew D. Huberman?

  Not your lab.

• 1:40:12Speaker 07

  Not my lab, that's never happened. Yeah, seriously, it never happened. But, but, but they'll at least know that, hey, I've got a sense of what two capsules do, I've got a sense of what five capsules do, and so, but, in reality... Like, that's not what people do. They'll, they'll, they'll take a piece of blotter paper and they get a tiny little pair of scissors, a Swiss Army knife pair of scissors, and they'll cut up the tab of acid, which is like, you know, a quarter inch square or something. And, and they'll cut it up in ten little pieces. And it's like, I got, you have no idea, like, if it's equally distributed in that media.

• 1:40:46Andrew D. Huberman?

  Yeah, and we can chuckle about it. And, um, but to me, one of the reasons why this experiment around psychedelics, this cultural experiment and this legal experiment, we're seeing this now, but this was all attempted once before in the sixties and seventies. The difference was, it was all out in the street. The people in universities who were dabbling with this stuff, lost, most of them lost their jobs or were asked to leave through, you know?

• 1:41:14Speaker 07

  They lost their funding for this research minimally, and they had to move on to other topics.

• 1:41:18Andrew D. Huberman?

  That's right. So these are precarious times. I mean, we're at, we're at, we're at a key moment where everyone assumes that this is all gonna be legal in a few years. But I think that that's a premature assumption, frankly. But, um, and I'm, and let's touch on the legality and some of the things that are happening now. But what is microdosing psilocybin versus the sorts of dosages that you described before in the ten to forty milligram range? I've heard of people taking one or two milligrams of psilocybin every day as a way to quote unquote, and for those listening, I'm just making air quotes with my fingers, increase plasticity, which is, which is a term that I personally loathe,

• 1:42:01Andrew D. Huberman?

  because what does that mean? I mean, you don't really want your brain to be plastic, because you, you need to make predict, you need to maintain your ability to make predictions. Yeah, I mean.

• 1:42:10Speaker 07

  Order and chaos, like prediction, you're, you need models of the world. You need heuristics, like.

• 1:42:15Andrew D. Huberman?

  Plasticity is never the goal, or plasticity is never the goal. Goal-directed plasticity is the goal, right? Learning a language, reshaping your experience to a trauma, altering the perception of self. But plasticity is a process, like.

• 1:42:32Speaker 07

  Yeah, schizophrenia is a lot of plasticity.

• 1:42:35Andrew D. Huberman?

  Exactly, right, right. It might even be, there's one theory that it's extreme ongoing plasticity and that's why people never create stable representations of anything. That's a kind of a minority view out there, but, um, so what's the business with microdosing? And is there any clinical evidence or peer reviewed published evidence that it works, quote unquote, to make people feel better about anything?

• 1:42:59Speaker 07

  So, microdosing is, is, is the aim of taking, again, something around a tenth of what would be sort of an entry level psychedelic dose for whatever compound. So, so like, yeah, with psilocybin, usually people, almost never do people have like pure psilocybin, like one milligram of psilocybin would be in the range of a microdose. More likely, people are gonna have, you know, mushrooms, so like something like a, a half of a, of a gram of mushroom.

• 1:43:27Andrew D. Huberman?

  I know people that are doing this every day. They're doing these every day. It's like in their, like the same way that I take, uh, like I'm, I'm personally, I'm not recommending other people do this, but I take some, I'm a fan of L C L carnitine lately. I've been kind of experimenting with that a little bit, which is not a psychedelic compound. I take it every day and that they're taking their psilocybin every day. That's their supplement.

• 1:43:47Speaker 07

  Yeah.

• 1:43:48Andrew D. Huberman?

  Um, so.

• 1:43:49Speaker 07

  So, yeah, the, the claims are, and there are a number of them, there's two general ones. One is, is sort of acting in, in place of the ADHD treating drugs. So the psychomotor stimulant. So like a better version of Adderall. The other claims are essentially a better version of, of the traditional antidepressants, a better version of Prozac.

• 1:44:12Andrew D. Huberman?

  So people are taking both for attention deficit and for depression.

• 1:44:16Speaker 07

  Yeah. And, and the aspects of those disorders that, you know, we all have a, a degree of, you know, just like amphetamine is going to increase the focus of, at the right dose of anyone who takes amphetamine, pretty much, whether you're ADHD diagnosed or not. Um, the idea is, is that, you know, that there may not be a necessarily a, a clear divide between the therapeutic need and, you know, positive psychology, you know, even improving mood and focus, you know, uh, you know, so it's not necessarily correcting, you know, uh, ADHD, but improving focus to supercharge, you know, your, your life. And so those are the claims. I am.

• 1:44:57Speaker 07

  So, so, none of the peer-reviewed studies that are, have much credibility, none of them have shown a benefit. And they've tried, now, there's only at this point, four or five studies that, and I think for things like this, you really need double-blind research, because the effects, I mean, there was one study done in Amsterdam where people knew they were taking psilocybin truffles, basically same as mushrooms, or more like the roots, the mycelia.

• 1:45:25Andrew D. Huberman?

  Microdosing, though.

• 1:45:26Speaker 07

  Well, taking of what would be considered a, a, a, a microdose, and then doing some, some cognitive measures before and after, and the types of thing that, you know, like a lot of cognitive measures are measured on the order of reaction time and milliseconds. I mean, and the types of effects you get, as you could imagine, are ones that like, would be, you would totally expect could be there from either a practice effect, or, or an expectancy effect, a placebo effect. So, you know, for something like these claimed, you know, you could imagine a sort of an increased focus, you know, enhancement of cognition, these are like, gonna be more subtle effects that you really need a, a, a good placebo control for.

• 1:46:11Speaker 07

  The handful of studies that have done that have shown, they've ranged from finding no effect whatsoever, to just a little bit of impairment, like impairing someone's ability to do time estimation and production tasks. So, you want an accurate sense of time, at least if you're navigating in the real world. It's different if you're on the couch on a heroic dose, for therapeutic reasons, where you're safe, but if you're crossing the street, if you're getting, you know, in your work-life. Yeah, which is what, the way people are claiming to, you know, use, that it helps them be a better CEO, like, you want an accurate sense of time. So, if anything, the data suggests that it makes it a little bit less accurate. And, and there's evidence that someone feels a, a little bit impaired, and they feel a little bit high.

• 1:46:57Speaker 07

  So, in terms of, you know, you call that abuse liability in research, not surprising, you take a little bit of, of a drug, that can result in a, some type of a high, and you take a little tiny bit of it, you'll feel a little bit high. So, um, you know, none of the, so far, no studies have, have shown, you know, any increase in creativity, enhancement of any form of cognition, or, or a sustained improvement in mood. No studies have actually looked at the the the the system of microdosing that the aficionados are claiming. And there's a couple of models out there, but but folks like Paul Stamets and others,

• 1:47:39Speaker 07

  they'll have particular formulas. They're like, you need to take it one day and then take so many days off and take it every four days. And I don't want to get into whose model is what, but it's always something like that, some pattern of use, usually not every day. And and the claim is that it's not just, you know, sometimes people get benefit that first time when they take it, but they really say you need to be on it for a while, like a few weeks in, you may start to notice through this pattern of of using it and you you're you're feeling the benefits on those off days, like the three or or two days in between your active doses. So those are the claims. Again, we don't know that there's any truth to that working, but studies have not been done to model

• 1:48:21Speaker 07

  that. So that's a big caveat. We as a field, I say, we as the as the scientific field ha- have not done the studies to really model, you know, what the real aficionados are claiming, you know, you know, where the therapeutic benefits come from. That said, it's it's it's almost assuredly there's a good amount of placebo there. But but the caveat to that is like, almost everything in medicine or therapeutics, there's and is going to have some degree of placebo there.

• 1:48:50Andrew D. Huberman?

  Relief effects are are I have a colleague at Stanford, Aliya Crum, who has published really beautiful work on belief effects that show that essentially you give the same milkshake to two people, you are two groups of people, you tell them that one contains a lot of nutrients, the other is a low calorie shake. There there the insulin response.

• 1:49:10Speaker 07

  Amazing.

• 1:49:11Andrew D. Huberman?

  Varies dramatically between the two or two people, two groups, rather, doing equivalent amounts of of physical movement. And you tell one group that it's going to be good for them and help them lose weight, and they lose on average eight to 12 pounds more doing the exact same. Patterns of movement. So, and I think that these belief effects boil down to all sorts of kind of network-wide neuromodulation, things of that sort.

• 1:49:33Speaker 07

  And then the work at Harvard suggesting that even if you don't have deception, you give a placebo and say, "This is a sugar pill."

• 1:49:40Andrew D. Huberman?

  Right.

• 1:49:40Speaker 07

  You know, and tell them that. And they could still treat things. I think irritable bowel was the first thing they looked at.

• 1:49:46Andrew D. Huberman?

  Right.

• 1:49:46Speaker 07

  And so, there's a huge, so there's a reality there.

• 1:49:49Andrew D. Huberman?

  Right.

• 1:49:49Speaker 07

  There's a necessity in developing drugs to make sure it's not only that, but in the actual practice of medicine, hopefully what you're always getting is some underlying direct efficacy plus the placebo that enhances that. Now, it could be that this is, the real question is, is the microdosing, are those claims 100% placebo, or are they only part placebo and part real, you know, quote-unquote, effect? My bet is, and this is totally based on anecdotes, that I think there is probably a reality to the antidepressant effects. I find that more intriguing.

• 1:50:25Andrew D. Huberman?

  Well, subtle.

• 1:50:26Speaker 07

  Because of the suffering with depression.

• 1:50:27Andrew D. Huberman?

  Right.

• 1:50:28Speaker 07

  Even if it's a, it, it wouldn't be as interesting as I think what we're doing with high-dose psilocybin or psychedelics to treat depression. It would be, if this is developed and there's a reality, it would be more like a better, you know, perhaps a better SSRI, a better Prozac.

• 1:50:44Andrew D. Huberman?

  Which are similar.

• 1:50:45Speaker 07

  That being said, we need more tools than fewer tools in the toolbox. And it shouldn't be that surprise, like even before the, going back to the tricyclics and the MAO inhibitors, going back to the 50s, like augmenting extracellular serotonin in one way or another, for many people, leads to a reduction in depressive symptoms. It wouldn't be that crazy for chronically stimulating a subtype of serotonin receptor that you have an antidepressant effect. So, I think if I had put my bets on it, that there's, if there's anything real, it is in that category. Although, I'm very open to like, maybe there is something to the creativity, to the, you know, improved cognition, which covers many

• 1:51:26Speaker 07

  domains in and of itself. But my, my greatest hopes are on the, on the antidepressant effects. That said, in the big picture, I think all of, the most interesting thing about psychedelics are the heroic doses. I mean, the idea that you can give something one, two, three times, and you see improvements in depression months later, and in addiction.

• 1:51:49Speaker 07

  You know, over a year later and with these, you know, people dealing with potentially terminal illness, I mean, it's, I mean, I'm interested in big effects.

• 1:51:57Andrew D. Huberman?

  Right.

• 1:51:58Speaker 07

  And I don't think you're ever gonna get the really big effects. There's also some concern that almost all of these common psych, the more common psychedelics, even counting MDMA, they have serotonin 2B agonist effects. And agonizing serotonin 2B has been shown to lead to heart valve formation problems, morphology issues, so valvulopathy. And so this is why fen-phen was pulled from the market.

• 1:52:27Andrew D. Huberman?

  The diet drug.

• 1:52:29Speaker 07

  Yes.

• 1:52:29Andrew D. Huberman?

  Very effective diet drug.

• 1:52:30Speaker 07

  Right, right. And it was the portion of that combination that had the serotonin 2B activity that was the problem. And so, we don't know, so all of the toxicologists I've ever spoken to about this would, you know, say, and cardiologists say like, look, hey, if there was some concern there, it's not applicable to the whole idea of you taking something a few times therapeutically within a lifetime. But the idea of taking something like, you know, twice a week for years, I mean, even the hippies back in the 60s weren't doing that, right? Like, there's not even these natural, and even if they, even if there was some heart

• 1:53:11Speaker 07

  valve disease problem that stemmed from psychedelic use, who's connecting those dots? That's not showing up in the clinical charts for anyone to figure out. So, there is, and just theoretically, there is more of a concern, if something's gonna happen with heart valves, it's more likely that those issues would arise when someone's taking these things, like, yeah, let's say, twice a week for the next five years. And so I do wanna throw that out to people to really consider.

• 1:53:41Andrew D. Huberman?

  Right, yeah, it's something I hadn't heard before, that in micro sounds safer, microdosing as opposed to heroic or macrodosing. And yet, unless, and in the context of your lab and other labs doing similar work, you've got this, people checking blood pressure, you've got people that are really monitoring your psychological and physical safety, when people are out there microdosing, it sounds like there's a potential, either through this serotonin 5H2B receptor or other mechanism, that maybe there could be some kind of cumulative negative effects. And I think that's a really important consideration, so I'm glad you brought it up. What about kids? So the brain is very plastic early in life.

• 1:54:25Andrew D. Huberman?

  It becomes less plastic as we age, although it maintains some degree of plasticity throughout the lifespan. The year 25, not the year 25, but rather the age 25 years is sort of an inflection point where the rigidity of the neurotrophic system seems to really take off. Of course, people don't wake up on their 25th birthday and find they have no neuroplasticity, whereas the day before they had a lot. These are, you know, it's plus or minus, whatever it is, a year or two. But depends on the individual.

• 1:55:00Andrew D. Huberman?

  However, the young brain is very plastic. And I could imagine there could be great risks. Who knows, maybe even benefits, but I'm certainly not thinking about those. I'm mainly thinking about the risks for young people taking psychedelics. Are there any trials looking at people in clinical trials, this would be under the age of 18? Has anyone explored this in a rigorous way? Given the potential to exacerbate psychotic symptoms and bipolar symptoms in some people,

• 1:55:35Andrew D. Huberman?

  is there heightened risk of that? What's the story with age of use in psychedelics for therapeutic purposes?

• 1:55:42Speaker 07

  There's no formal research, although there's a very high chance that there will be. And so this is one of the very interesting things folks may not realize or appreciate about the FDA approval process. So the FDA already in multiple instances has signaled that they're, they want to see those studies.

• 1:56:00Andrew D. Huberman?

  Before?

• 1:56:01Speaker 07

  Well, not before it's approved as necessarily as, you know, for adults, but they're going to eventually want to see, in fact, so the MAPS group that's developing MDMA for PTSD.

• 1:56:14Speaker 07

  Already signaled that that's kind of on a list of interest. And there's even some incentives in the FDA pathways for incentivizing folks to explore that, that use in young people. I know in some of the work that I helped with in pushing psilocybin into phase, phase two B clinical research, the FDA, you know, said, well, why, why can't you give this to kids? It's like, are you aware that depression is a problem with adolescents? Like, you know, like, and it's really interesting because this FDA is very concerned about pseudospecificity.

• 1:56:57Andrew D. Huberman?

  What do you define pseudospecificity?

• 1:56:59Speaker 07

  You put out a drug and say, oh, this is good for men, but not women. This is good for black folks, but not white folks. And now, sometimes there's a very good rationale for that, like when we're talking about hormones and for a specific, you know, for, for, for, for men versus women. And there's certain, you know, issues, you know, you know, certain disease states like maybe sickle cell anemia that's more relevant.

• 1:57:23Andrew D. Huberman?

  Taste acts, things like that.

• 1:57:24Speaker 07

  Yeah, exactly. You know, but absent of something that, they're very concerned about saying, oh, this is for this type of person, but not that type of person. So age is one of those things. And also this recognition, you know, much like the emphasis at NIH with, you know, with, you know, with rodent studies and human studies that like, you can't just say you're studying men, or just, you need a rationale if you're only studying.

• 1:57:46Andrew D. Huberman?

  Yeah, to be clear to people, there's, it's a recent switch, but there's a stipulation in every federally funded grant that both sexes, we don't refer to gender in scientific studies unless it's a study of gender per se. We refer to sex, meaning biological sex. So that there's a stipulation that in order to receive and continue to receive funding, you have to do studies on both males and females of that species, including humans.

• 1:58:14Speaker 07

  And at least, even if you're not powered for it, at least looking at that in exploratory analysis, like as a grant reviewer, I'm charged with looking at, you know, did they address like sex as a biologically relevant variable?

• 1:58:26Andrew D. Huberman?

  Right. Does the same, does the same drug have different effects in males versus females?

• 1:58:31Speaker 07

  Right. And you could at least look at the trends, even again, if you're underpowered to look at those between subject type effects.

• 1:58:37Andrew D. Huberman?

  Which is a great shift that didn't exist in, you know, 10 years ago. Sounds like we're both on grants panels. As study section members, you didn't have to do that. Now it's a, it's an important biological variable. If you don't look at that, you essentially won't get your, your funding.

• 1:58:53Speaker 07

  And age is a similar thing. So it's the whole idea like, man, if something could help kids, like what's the rationale? So I think there's gonna be, now obviously you're gonna have in those studies at least just as much, probably more, it should be more, you know, of a caution, cautionary approach. It's probably gonna be, you know, it would certainly, whatever disease states are like, they're gonna have to be probably treatment resistant, at least as a first step, you know, hey, the kids tried. Yeah, yeah. And, and so all of that in the mix, but hey, you know, if this stuff really helps people, you know, that are 25 or 30, like what's the rationale that it won't help a younger person? You know, and there's these generic kind of concerns about the developing nervous system

• 1:59:37Speaker 07

  is more susceptible to prob, I mean, it cuts both ways because it's also more plastic generally and adaptable and maybe resilient to injury in certain ways. But, you know, you hear the rhetoric about kids, their brains and drugs, and it's like the developing brain is a special concern.

• 1:59:55Speaker 07

  So yeah, but I think we're gonna be seeing research eventually.

• 1:59:58Andrew D. Huberman?

  That's, it's interesting. I went to the high school that is infamous sadly, Gunn High School, for having the highest degree, at least at one point of suicide, high suicide rate.

• 2:00:10Speaker 07

  Wow.

• 2:00:11Andrew D. Huberman?

  And a very large number of suicides. This was written up in the, in the Times and elsewhere.

• 2:00:15Speaker 07

  Is it a very academically successful school?

• 2:00:18Andrew D. Huberman?

  It's a very academically.

• 2:00:19Speaker 07

  There's a lot of high pressure.

• 2:00:20Andrew D. Huberman?

  Yeah, very academically demanding school. To the point where they've restricted, the kids will meet often at 6:30 a.m. or 6:00 a.m. before school for study groups and things of that sort. So some of it may relate to that. But I have to say that even prior to all that academic pressure, when I went there, it wasn't, the pressure wasn't like that, that, you know, we had an unusual number of suicides for whatever reason. And, you know, and so the idea of kids being prescribed, and I want to emphasize prescribed, not just using, but prescribed psychedelics for therapeutic purposes, I think might make some people balk, but. The idea of kids killing themselves should also make people balk.

• 2:01:05Andrew D. Huberman?

  And so I'm relieved to hear that there's going to be a rational, scientific, safe, clinical trial-based exploration of this.

• 2:01:16Andrew D. Huberman?

  I want to ask you about the current status of these drugs and compounds. I'm pretty active on social media, more so on Instagram than on Twitter. But as I have been on Twitter a little bit more recently, I've noticed that there's a lot of dialogue around your account and other people's accounts around a couple of themes related to psychedelics. First of all, what is the status of the transition to legality for prescription purposes? So, medical doctors, MDs prescribing it legally for therapeutic purposes? That's the first question. The second question is, what is the status as it relates to possession and criminal charges?

• 2:02:00Andrew D. Huberman?

  So, for a long time, I lived in Oakland, where we were one day told, not too long ago, it is now quote-unquote "decriminalized" is what I was told. Double check, people. But what does that mean? And then, the other issue, and the third question, and we can parse these one by one, is this issue of, let's just say, I'm aware of a lot of investor dollars going into companies that are essentially companies focused on psychedelics as therapeutics, or psychedelics generally. I have to assume that they are investing in anticipation of a shift in the legal status.

• 2:02:40Andrew D. Huberman?

  And there's a lot of interest now, like, will psilocybin become a taxable thing, just like marijuana? So, let's start with the question of like, what is going on in the US legally? Is it illegal to possess and sell and use these compounds? My understanding is you can still go to jail for having these compounds in your possession, or for selling.

• 2:03:05Speaker 07

  Right.

• 2:03:07Speaker 07

  Even though it's a, the, the legal landscape is very different than with cannabis, there are some similarities. So one of the similarities is that regardless of what local municipal, you know, whether city or state has decriminalized, um, and that, that word itself can mean many things. So the devil, some, some forms of decriminalization is close to what folks would call legalization and others are like pretty weak, you know, just saying, we suggest that the police make it their lowest law enforcement priority, that type of thing.

• 2:03:39Andrew D. Huberman?

  Turn the other cheek, kind of thing.

• 2:03:40Speaker 07

  Right. But even the, the cops can still choose to.

• 2:03:43Andrew D. Huberman?

  But someone could get, could get pulled over for one thing, searched, and then by definition, if it's illegal and they find it, then they have, they have to do something about it.

• 2:03:52Speaker 07

  And that'll probably be determined by, you know, like both judicial precedent, is it going to be thrown out? And, and just the local prosecutor, you know, even before, like, are they going to choose even at post arrests are going to pursue to really, you know, go after those charges, make those charges stick. So I think that's still in play and is going to depend on the municipality. But like cannabis, federally, these are all Schedule One compounds.

• 2:04:15Andrew D. Huberman?

  Which means they're illegal.

• 2:04:16Speaker 07

  Which means they're illegal. Uh, the caveat to that, just as has always been the case since Prop 215 in California with cannabis in 96 is that, hey, 99% of, of drug enforcement is done at the local and state level. The DEA, which is the federal level of law enforcement, is a tiny fraction of the arrests that, I mean, most people that are arrested for any drug are done by local or state level, um, authorities. But it's still technically, you know, illegal. And so you can, and they could potentially, depending on the ambiguity of the local law, they, even those local officials could charge you with a, a federal crime. Um, and theoretically, the feds could always come

• 2:05:01Speaker 07

  in. Now, although you'll, you know, again, a similar, you know, case with the whole cannabis history, it was the The feds came in in the early days with the folks that were basically highly visible. They went after Tommy Chong for selling bongs. But, you know, I remember him being on The Tonight Show one time and I think it was back in the Jay Leno days. He says, "But all along the Santa Monica Boardwalk, like every shop sells bongs. How did you go to prison for a half year for bongs?" It's because he was, and they're-

• 2:05:29Andrew D. Huberman?

  Because he was famous.

• 2:05:30Speaker 07

  Because he was, you know, Tommy Chong. And, and there were some high-profile cannabis groups of, you know, that were distributing it and they were very vocal. Those were the ones raided by the DEA in the early days, not the ones kind of keeping to themselves, keeping it quiet and just doing their thing. So there's always the potential for selective enforcement. And so, you know, and like this initiative in Oregon, which is a state level legalization of psilocybin therapy, which is really interesting, you know, part of their plan for two years is to figure out how to integrate with the federal level. And I don't know how that's going to go because like unless you rewrite the Controlled Substances Act, it seems like the best you're going to get is a tolerance from the federal government.

• 2:06:17Speaker 07

  And, you know, and that could be very, you know, hey, you change administrations.

• 2:06:22Andrew D. Huberman?

  And this is psilocybin by prescription from a medical doctor? Or you're talking about therapists who have master's degrees or PhDs or self-appointed coaches or something like that, administering psilocybin, but without any oversight?

• 2:06:41Speaker 07

  So this is all getting figured out in the Oregon case? And again, there's that two-year period of like, basically, we're going to figure this out and so-

• 2:06:48Andrew D. Huberman?

  What is it with Oregon?

• 2:06:49Speaker 07

  They're ahead of a lot of, you know, euthanasia.

• 2:06:52Andrew D. Huberman?

  I love the state of Oregon, but it's interesting how you have these pockets. Oregon, Vermont seems to be one, you know, you got these kind of pockets where people are experimental with plant compounds. They seem to be green, woodsy areas for, at least in my mind. But there's sort of a culture around plants and the use of plants as therapeutics.

• 2:07:13Speaker 07

  And combine that with the West, just more geographically of more of the, the anti, you know, federalism, the anti, I mean, the Oregon ranchers from several years ago that held up the, you know, the whatever wildlife place, you know, and that was a big showdown with the feds, you know, and the, you know, just kind of, the West is kind of known for- You know, more of those issues. So he combined the two, the hippie dippy California Oregon vibe.

• 2:07:40Andrew D. Huberman?

  Yeah, although I would argue it's becoming less hippie dippy the um than although it was. That there's always been a tradition, not just in the culture around drugs, but um certainly in academia and in tech, etc. That the West eh has been a place where people have tried to throw off traditionalism and kind of lineage. And like who your parents are, what school you went to and um and the past as a determinant of what's next and exciting about the future. Whereas um and here we are, an East Coast institution guy and a West Coast institution guy. Um, I I think that it's this idea of kind of innovation and the future versus do we stay grounded in history and tradition?

• 2:08:25Speaker 07

  Right.

• 2:08:26Andrew D. Huberman?

  And of course, there are great institutions on both sides. What's interesting is that um Hopkins, Johns Hopkins Medical School, I think of as a a real like East Coast academic institution. It is on the East Coast, but here you are uh doing these very pioneering and important and exploratory and studies in a certainly not a hippie dippy environment.

• 2:08:49Speaker 07

  Right. Oh, yeah. Hopkins is not a. Psychiatry department, even amongst psychiatry departments. And as a psychologist in a psychiatry department, psychiatry is certainly more conservative than psychology, even within academics. But even amongst psychiatry departments, it's a very conservative department.

• 2:09:05Andrew D. Huberman?

  So we've got the law at the federal level. We've got the law at the state and local level. And then we've got this question of whether or not it's going to be physicians, so MDs, people with PhDs or master's degrees, or whether or not it will be kind of a free for all.

• 2:09:21Speaker 07

  Right.

• 2:09:21Andrew D. Huberman?

  Um, for for consumption.

• 2:09:23Speaker 07

  The life coaches.

• 2:09:24Andrew D. Huberman?

  The life coaches and and and the general public. I mean cannabis.

• 2:09:27Speaker 07

  Yeah.

• 2:09:28Andrew D. Huberman?

  I I'm not a pot smoker. I just it it's never appealed to me. Um, that's just me and my my pharmacology. But um, you know, you can buy cannabis most places in the US without a ton of risk, it seems, right? Um, are we going to see a time in which? You can essentially go into a shop on Abbott Kinney Boulevard in Venice, California. And right now you can go buy marijuana if you have a marijuana card. That's my understanding. I see a lot of people going in and out of these stores. Um, the police certainly have no problem with it. Is there gonna come a time where people are gonna just go buy psilocybin? Uh, do you think?

• 2:10:07Speaker 07

  Like they do in Amsterdam and have for a long time.

• 2:10:09Andrew D. Huberman?

  Do you think that time is coming?

• 2:10:10Speaker 07

  Um, I think so at, at, at a certain point. And, uh, I don't know how long. Um, I, I, it's hard to imagine our current level of drug criminalization holding up for, and I'm thinking like large spans of time. Like really in a hundred years are we gonna be doing this 500 years? Like, how could that, it's not gonna be sus- sustainable.

• 2:10:39Andrew D. Huberman?

  But in five years, for instance.

• 2:10:40Speaker 07

  So I don't think so in the United States. Um, I, I, I do think eventually you're gonna see something like that 'cause there's gonna be no way, and, and I think we're gonna, I hope that we're gonna eventually come so strongly, uh, we're gonna move on from this model of criminalizing drugs, that we're really gonna focus on regulating drugs at the right level for that drug. And I, I like the word regulation better than legalization. So, I mean, I could imagine what one day regulation, smart regulation might mean for psychedelics. Maybe it could mean that there will be, you know, whether or not you have a diagnosis of a problem. It, it may be that even for personal exploration, you can do this legally.

• 2:11:23Speaker 07

  But you first have to maybe take a court, get a driver, and this has been, I'm not the first to say this, but get equivalent of a driver's license. You have to go to, uh, get some sort of training. Maybe your first number of experiences need to be with, uh, with trained guides who can facilitate it, and then the, the public health information for anyone using this, that this is what riskier use is, all use is gonna have risk. This is what riskier use is, this is less risky use. These are the factors. So I think eventually we're gonna be get, for any, but I would say the same thing for like methamphetamine and, and, and, you know, heroin and cocaine, like all of these drugs. It's hard to imagine the current approach of just feeding a black market and really exacerbating a lot of the harms from drugs, you know?

• 2:12:08Speaker 07

  You know, that happens under the current model. It's hard to imagine that maintaining. That isn't to say I think it should be in all of the 7-11s, you know, sold to kids at the other.

• 2:12:18Andrew D. Huberman?

  I would hope not.

• 2:12:19Speaker 07

  But I do think it's probably not going to be soon in the United States. I do want to make the major point that even if psychedelics had never been made illegal, I think the exact, the trajectory of the medical research right now would still need to happen. If it's effective as an antidepressant, like, we need it to be, you know, there's all the evidence suggesting that whatever disorder we're talking about, the efficacy is going to be increased and the risks are going to be mitigated drastically in the types of models we're talking about with the screening, with the preparation, with the integration of cognitive behavioral therapy or what have you, depending on the disorder you're treating, with the integration afterwards with the professionals.

• 2:13:03Speaker 07

  So, um, it, it, it, we would be doing it anyway, so it's not like this versus that. So I don't see it as a race between the decriminalization or legalization of these compounds versus their medical development. Some people who are psychedelic fans

• 2:13:18Speaker 07

  get all into a bunch about the medical development. They say, you guys want to like, you want to, you want to keep it only for, you know, for your medical research and I retire and you want to be, you know, in control of it as academics. And my take is, I didn't make it illegal for anyone. We're only moving the needle in one direction. And again, even if it was already illegal, and, and because, and I've done plenty of survey research of people reporting, they took mushrooms for fun or for personal exploration. And they said, my God, why am I smoking? And they quit smoking 20 years because of it. Or it's helped with their depression, or it's helped with them overcoming alcoholism or these. Sometimes that happens out of the blue when people use psychedelics. Nonetheless, obviously, the efficacy rates are going to be higher when you bring it into

• 2:14:03Speaker 07

  these medical models and it's going to be safer. So we're going to, you know, so we need to be pushing that. And my best guess is that MDMA is going to be approved within the next three years.

• 2:14:14Andrew D. Huberman?

  For a prescription by a physician?

• 2:14:16Speaker 07

  Yes, in, and not just, you know, take two and call me in the morning, but in the clinics, the way that those, those PTSD trials are being run. So the MDMA would be approved for PTSD and every disorder needs to be looked at separately and it's going to only be approved for those things. Now,

• 2:14:32Andrew D. Huberman?

  There's going to be questions about- Approved and legalized and regulated, or, you know, now we're getting into the nuance. I think when people hear it's going to be approved in two years, they think that they'll be able to buy and sell and use MDMA without legal consequences, and I do not think that's going to be the situation. Right, that's not going to be the case. It's not the way it is. And I will say that, um, I think the quote-unquote psychedelic community, I mean, they've been doing what they want to and will carry on doing what they want to anyway, right? It's not like the legal status has prevented them from doing what they're doing. In fact, unlike Leary and Timothy Leary and Huxley and, you know, and some of the others that were very vocal and lost their jobs and some who even went to jail, et cetera.

• 2:15:16Andrew D. Huberman?

  I mean, you've got a lot of public figures now, like McKenna and others, who are just basically out there talking about psychedelics. Michael Pollan, who is more of a writer, foodie guy, psychedelic dabbler, writer guy. I know he's kind of a polymath, but, you know, the legal status didn't seem to hinder their, at least, online careers. I don't know, I haven't looked at their bank accounts, but I'm imagining they're doing just fine, right? So, the fact that work is happening inside of big institutions, I think it's important that you point out, and I'm just trying to underscore, that that's in no way antagonistic to what people are doing. It's in support of a different sort of mission, which is to explore the validity in different

• 2:16:00Andrew D. Huberman?

  contexts in a really controlled way, which I really, you know, I think it's a really important mission. I want to make sure that I ask you about the other really important mission that you're involved in with respect to psychedelics, which is not about depression per se, but is about neurological, neurologic injury, or head injury. I realize it's early days for this, but I think-

• 2:16:26Andrew D. Huberman?

  There's a lot of concussion out there sadly. There's a lot of TBI, traumatic brain injury.

• 2:16:31Speaker 07

  Yeah.

• 2:16:31Andrew D. Huberman?

  Not just from sports. I think people sometimes forget that it's not the, the major source of traumatic head injury is not football. It's not hockey. It's not boxing. It's not any of that stuff. It's construction workers and it's people. I mean, if you've ever seen the helmets that construction workers wear, I mean.

• 2:16:48Speaker 07

  The jackhammer. Oh my God.

• 2:16:50Andrew D. Huberman?

  The jackhammer.

• 2:16:50Speaker 07

  How could that not be just like?

• 2:16:52Andrew D. Huberman?

  I have a colleague that works on this in bioengineering and when you look at the, you know, we always think sports, but there are many people who make a living in a way that is, over time is detrimental to their brain and they don't have the option of just not being a professional athlete or something of that sort.

• 2:17:09Speaker 07

  And if they're not doing the construction, someone else needs to do it.

• 2:17:12Andrew D. Huberman?

  Someone else has to do it, right. And, and we forget, for some reason, and I too, it didn't occur to me until I heard it, like the, the people who are doing construction, um, and then of course with bike accidents and falls and things like that as well.

• 2:17:24Speaker 07

  Military.

• 2:17:25Andrew D. Huberman?

  Military, absolutely. So, um, what do you think is the potential for these compounds, particular psilocybin, but other compounds as well for the, um, treatment and possible even reversal of neurological injuries? And what, what sorts of things are you excited to do in that realm?

• 2:17:44Speaker 07

  Yeah. So this is definitely on the more exploratory end. So it's based upon, so, you know, this is sort of beyond the, the improvement of psychiatric disorders like depression, um, you know, or depression, anxiety associated with a terminal illness, um, or a substance use disorder, the addiction. So those are sort of psychiatric, you know, disorders. So this is, you know, um, these, you know, there are anecdotes of, of people saying, uh, that.

• 2:18:19Speaker 07

  That psychedelics have helped heal their brain. You know, they've been in one of these situations like in sports, a sport where there's repetitive head impact and they're claiming that, you know, using psychedelics has actually improved their cognitive function. For example, improved their memory, including improved their mood. But it's kind of more of the, you know, the cognitive function, things like memory are... Now, caveat is if you've successfully improved someone's depression, you can get some cognitive improvement too, but that's a more of a weaker, more indirect effect. But if you take these anecdotes and you combine it way across orders of analysis

• 2:19:01Speaker 07

  to the rodent research from several labs like David Olson, Brian Roth, these folks that have shown different forms of neuroplasticity unfolding

• 2:19:14Speaker 07

  after, like sort of post-acutely, so after, in the days following the administration of psychedelic compounds, a variety of psychedelic compounds, and even some non-psychedelic structural analogs, that you see these different forms of neuroplasticity. So the growth of dendrites and new connections being formed with different neurons. So that, those effects may be at play and they improve in the psychiatric treatments that we're dealing with. That, we don't know that. It seems like a decent guess and we're going to be figuring out whether that's the case. But another potential that that sets up is that maybe that's what's going on

• 2:19:57Speaker 07

  with these claims of improvements from neurological issues, that there's actually, you know, a repair of the brain from injuries underlying, you know, things that, you know, situations where there's repetitive head impact. Perhaps there's a potential for helping folks recover from stroke and disorders like that. There's a wide variety of disorders. Now, it's a bit of magic and a bit of like, it's something that the enthusiasts kind of can do some hand-waving and claim that this is already known. It is more exploratory. But what I'm hoping to do is some work with retired athletes.

• 2:20:43Speaker 07

  Who have been exposed, but by the nature of their sport, for example, NNA athletes in the UFC, who have been exposed to repetitive head impacts, like a lot of sports, a lot of, you know, sports expose people to, and who are retired from the sport and are suffering from, say, depression, which can impart result from those types of, that history of head impact. See if we can fix the depression, but then also, as a cherry on top in a more exploratory aim, see if we can have evidence of improvement in cognitive function and associate, like using MRI, see if it affects gray matter over time, these types of things, to see if

• 2:21:28Speaker 07

  there are actually some evidence of this improved, like this more direct repair of the brain. But again, it is very sort of like, we've got some rodent data, we've got some human anecdotes.

• 2:21:41Andrew D. Huberman?

  We will acknowledge it's early days and we look forward to seeing the data. I appreciate how cautious you are and tentative you are, you're not drawing any conclusions. I think from a purely logical and somewhat mechanistic perspective, I mean, if we assume that lack of ability to focus or degradation in mood is the reflection of neurons in the brain, I think we can agree on that, some dialogue between neurons of the brain, and that what needs to be changed is the nature of that dialogue, AKA neuroplasticity. We know that reordering of neural circuitry require, in the adult, requires these things

• 2:22:24Andrew D. Huberman?

  like intense focus followed by rest, et cetera, but the basis for that, like beneath focus is the mechanism, is a mechanism rather, beneath the bin that we call deep rest is a mechanism, and those mechanisms are neuromodulator driven. So to me, you're, I'm not reviewing your grant, but from a rational perspective, it seems that drugs that increase certain neuromodulators, like serotonin or dopamine, in a controlled way, and then coupling that with learning of some sort, sensory input of some sort.

• 2:23:02Andrew D. Huberman?

  It makes sense that that would lead to, could, I should say, lead to reordering of circuitry that would allow for better thinking, better mood, many of the same things that you've observed in the clinical trials for depression. So the rationale is really strong. I think that's a very exciting area. You know, I get asked all the time about TBI and traumatic brain injury. And right now, you know, it's kind of, there isn't a whole lot that people can do. And people are dabbling in the space of, you know, hyperbaric chambers, and people will do sauna and breath work, and you know, and people are kind of, you know, clipping at the margins of what really is a problem that resides deep to the skull. So I think, I just want to applaud that the exploration, I think it's great, provided

• 2:23:47Andrew D. Huberman?

  that exploration is being done in a controlled way. It sounds like that's what you're doing with the UFC.

• 2:23:53Speaker 07

  Yeah, so that's, that, you know, we, they were really gracious and had myself and a few of my colleagues out to their headquarters in Vegas.

• 2:24:01Andrew D. Huberman?

  Impressive place, right?

• 2:24:02Speaker 07

  And it's in process, you know, there's a dialogue going on there. I'm hopeful that there's going to be some, some work with them, but it's, it's in process now in terms of exploring that. There's a real interest and I'm, I'm just really impressed by the organization and their commitment to athlete health and we'll see.

• 2:24:20Andrew D. Huberman?

  Yeah, I am too. We, we have a colleague out there, we're doing a little bit of work with them, Duncan French, who's a serious academic in his own right. And I think when people hear UFC, they just think about the octagon and fighting and, you know, pay-per-view fights and things. But in talking with them, and I'm sure you've had these discussions as well, that they are very much interested in the health and longevity of their fighters. They are also interested in the health and longevity of their fighters being a template for how to treat traumatic brain injury and improve human performance in other sports and in the general public. And I think it's not an image of the UFC that is commonly comes to mind because they haven't been, you know, particularly verbal about it in the press. But I think it's great they're bringing in academics, I mean, geeks like

• 2:25:05Andrew D. Huberman?

  us, going to the, out to the UFC Performance Center. I mean, you do MMA, but I'm basically just a geek walking through the place. But the fact that they're interested in talking to scientists is really.

• 2:25:16Andrew D. Huberman?

  I'm biased here, but a point in their favor. Along the lines of other groups and individuals that have impacted the space that you're working in, in this pioneering of the psychedelic space. You know, a few years ago, I think if someone submitted a grant saying, I want to study how psilocybin impacts human depression, I'm guessing, having worked on these panels before, that the response might have been closer to, well, we need to do a lot of studies in rodents and a lot of studies in primates. And then maybe, just maybe, we could explore these drugs because the National Institutes of Health actually has a whole institute devoted to addiction, right, of exploring compounds only in terms of their negative effects, right?

• 2:26:01Speaker 07

  Which is where I've gotten all of my NIH funding.

• 2:26:04Andrew D. Huberman?

  Which is so interesting, right? And it's a super important institute. I want to be clear, they're amazing people there. But philanthropy and foundations have been very important in supporting pioneering research. And so maybe we just talk a little bit about that. So your lab receives funding from taxpayer dollars through the National Institutes of Health? Is that mainly where your funding comes from?

• 2:26:30Speaker 07

  So our group has gotten some funding from, like, say, the National Institute on Drug Abuse, NIDA, for some, a small subset of the psychedelic work, but only for some work geared towards understanding these things as drugs of abuse. Of course, when you do a study, though, you can ask about the good, the bad, the ugly.

• 2:26:50Andrew D. Huberman?

  Show us how they're, explore how they're bad.

• 2:26:51Speaker 07

  Right. But while you're doing that, you can explore, like, you know, the good stuff, too, you know? But the large majority of the work, and the most interesting work, has been funded by philanthropy.

• 2:27:04Andrew D. Huberman?

  Private philanthropy.

• 2:27:05Speaker 07

  Now, I still have some grant support from NIDA outside of psychedelics. I'm shifting more and more of my Um, uh, my time towards, you know, focusing only on psychedelics and in fact, us getting the, the, the center level funding from, um, some really, you know, big picture philanthropists like helped me to start to make that transition. But groups like the Hefta Research Organization, Dennis McKenna, which is one of the founding members, the brother Terrence McKenna, who's by the way, an ethnobotanist, that's what his PhD is in.

• 2:27:38Andrew D. Huberman?

  What does that mean, ethnobotanist?

• 2:27:39Speaker 07

  Um, studying the, the, essentially the anthropology of, of, of psychoactive plant use. So.

• 2:27:46Andrew D. Huberman?

  You can get a degree in that?

• 2:27:48Speaker 07

  Yeah, yeah, yeah, you know, hanging out with cultures and studying their use of these compounds in the traditional ways.

• 2:27:54Andrew D. Huberman?

  At Hopkins?

• 2:27:55Speaker 07

  Um.

• 2:27:56Andrew D. Huberman?

  There's, that, that degree exists at Johns Hopkins?

• 2:27:58Speaker 07

  I don't, I don't think that degree exists at Hopkins, but I mean, the, the kind of the most, and, you know, as you, as you'll, as you know from academia, I'm, I'm not, you know, sometimes folks, I'm not sure how many people's PhD is actually in, um, ethnobotany or if it's actually in something else. But the real focus is like, my degree is general experimental psychology.

• 2:28:19Andrew D. Huberman?

  Ten thousand kids out there just decided they're gonna major in ethnobotany, but you know, the.

• 2:28:24Speaker 07

  I mean, one of the pioneers of the psychedelic area before Leary and before, and actually, he was late even for the human researchers, like folks like Humphrey Osmond and Avram Hoffa and Sidney Cohen were earlier, but even before those folks, um, Richard Schultes at Harvard, he was, I mentioned him earlier in the conversation, discovered all of this, you know, these various tribes using ayahuasca or yage, a different name for the same thing, um, throughout South America and these DMT containing snuffs and all of this. So, you know, that was, you know, um, ethnobotany, this kind of, this kind of intersection of anthropology and these psychoactive, uh, plant, uh, compounds. So, so.

• 2:29:04Speaker 07

  The Hafter Research Institute, which Dennis is a founding and active member of, a board member, they have funded a lot of our early work. There's also an organization called the Beckley Institute, based in England, that Lady Amanda Fielding has been the head of, that has, they provided the first funding for our psilocybin smoking cessation research, and the Hafter came in and provided subsequent funding. But it's, and then there are other groups, Council on Spiritual Practices, a great guy named Bob Jesse funded some of the original work at Hopkins, looking at the nature of mystical experience, outside of treating

• 2:29:47Speaker 07

  disease states or disorders, but just understanding these, like, people take these compounds and astonishingly, you know, frequently will say, "That was the most important thing I've ever experienced." It's like, "What the hell is that?"

• 2:30:01Andrew D. Huberman?

  Yeah, I had someone mention recently, I think this might surprise people a little bit, certainly surprised me, I had a friend who adores his children, he's got three children, he adores his children, happy marriage, and great, great father, they're both great parents. And he told me that, as part of a clinical trial, he had a DMT experience, that he claims, he said, "I'd love to tell you that the birth of my children was as profound, but that was a more profound experience than the birth of my children, any one of them and all of them combined." And I was like, "Wow," and I've never done DMT, but I was like, "Wow, that's a pretty strong statement." Now, he did it in the context of one of these, you know, clinical explorations.

• 2:30:42Andrew D. Huberman?

  I assume that was part of a legal clinical trial, but the, I mean, that's saying something. It's saying something. I mean, he's a very rational, very grounded guy, otherwise, but...

• 2:30:55Andrew D. Huberman?

  So philanthropy foundations and then

• 2:30:58Speaker 07

  Most recently, and so I just, I can't, because I can't skip it. Our center level funding which came a year and a half.

• 2:31:03Andrew D. Huberman?

  I see.

• 2:31:04Speaker 07

  That's like, we, I mean, the Hefter Group, the Beckley Group, I mean, these are wonderful. I mean, these are people that have been holding the flame alive during the darkest hours, like the same thing with the MAPS organization on more on the MDMA side, like, holding that candle during the darkest years that, you know, so we, but, you know, smaller organizations connected to smaller, but growing over time, you know, pockets of wealth.

• 2:31:30Speaker 07

  But, you know, we basically limped on, limped along on a wing and a prayer until recently, when we got the seventeen million dollar gift, so that we could create a nominal center. And as you know, basically to the university, that means you get a certain number of dollars, and a lot of them, you can call yourself a center. You know, it's a capital investment, you know, staff, you know, equipment, salary support, which has always been the huge thing for us. But the seventeen million dollar gift, which was split between the, the, the Cohen Foundation, so Stephen and Alexandra Cohen, and they covered half of it. And the other half, the Tim Ferriss Collaborative, basically Tim and a few friends ponied up,

• 2:32:11Speaker 07

  that the, you know, divided the rest of that, half of that seventeen million dollar gift, and came together to just, I mean, it just, it's completely transformed our, the work that we've done and our ability to, you know, like, to fully delve into this area and not worry that, like, oh, if I focus on this, rather than putting another three NIDA grants on some other topic, that may or may not get funded, like, if I focus too much on the psychedelics, am I putting my career at jeopardy, but like, so

• 2:32:41Andrew D. Huberman?

  You're now not only a tenured professor, you're also a full endowed

• 2:32:45Speaker 07

  Right, so that came

• 2:32:46Andrew D. Huberman?

  By the way, when you say somebody is a fully endowed professor, I want to be very clear what that means, that means that there's funding.

• 2:32:51Speaker 07

  It might mean all of the above, but no.

• 2:32:54Andrew D. Huberman?

  I have no knowledge of your particular situation, but you you probably do.

• 2:33:00Speaker 07

  Just kidding.

• 2:33:01Andrew D. Huberman?

  But sure, the um, and these, what we're essentially saying is that funding, which does not change somebody's salary level. I just want to be clear because I think the general public isn't, um, there's no reason why they would um, understand all the the nuts and bolts of how this works.

• 2:33:16Speaker 07

  Academia is weird.

• 2:33:17Andrew D. Huberman?

  Yeah, academia is weird because we're not talking about increasing, we're not talking about an endowment that or philanthropy that went to increase um, Matt's salary. That that's something that's set at the university level. Um, it's always been said and it uh, is at least is still true now, which is that, you know, nobody goes into science for the money, at least not at the academic level. Um, uh, not at uh, in academia, but um, allows people to devote more of their time and energy to these uh, exploratory uh, realms like psychedelic research, or um, the case of my lab, the work that we're doing with David Spiegel's lab on on respiration, breathwork, and hypnosis for modulating brain states. These are not typically areas that the National Institutes

• 2:34:02Andrew D. Huberman?

  of Health and other major organizations have institutions set up to support. Now, there is an exciting initiative, uh, which is the NCCIH, which is complementary health.

• 2:34:13Speaker 07

  Right. It used to be NCAM.

• 2:34:15Andrew D. Huberman?

  Yeah.

• 2:34:15Speaker 07

  Yeah, they changed their name, yeah.

• 2:34:17Andrew D. Huberman?

  And now we're not just throwing out acronyms just to, you know, to bat back and forth acronyms, but I think what we're looking, what we're seeing now, uh, is a movement toward science and scientists and clinicians and the general public and philanthropy being engaged in this dialogue, which says, okay, there are problems in the world. Depression, head trauma, uh, psychological trauma, PTSD, ADHD. These problems clearly exist. The solutions are going to involve behaviors that are going to involve nutrition, supplementation, and social connection. However, there are drugs, there are compounds that can change the brain and allow the brain

• 2:34:59Andrew D. Huberman?

  to change its circuitry through experience. And psychedelics are one of of several others, but one of the, you know, powerful levers, it sounds like. And and I just want to say that I think the reason I reached out to you and I'm so excited to sit down and chat with you is because

• 2:35:19Andrew D. Huberman?

  I see very few people inside the halls of academia who have thrown their arms around this issue of psychedelics in a way and gone through the trouble of trying to find the funding to get it done, gone through the trouble of trying to set up clinical trials. I know what's involved in doing this. It's so complicated. It's so time consuming and painstaking and you've made real progress. I mean, you guys are publishing papers. There's a new dialogue emerging that isn't just books on bookshelves and, and you know, psychedelic, psychonaut gurus on the internet who also play an important role, but you're really moving this field forward. And I know there are others as well. There are colleagues

• 2:36:01Andrew D. Huberman?

  in England and others as well. We acknowledge them, but I just want to say personally that I'm like inspired and impressed by the way that you've gone about this and the level of rigor. I mean, when I ask you a question about serotonin, most people just kind of kick back to me, well, yeah, you got receptors and you got a ligand. But I mean, it's clear to me that you care about the details and that you care about the future of this area. And you also really care about these patients and these individuals. So I know I'm speaking on behalf of a ton of people now and in the future that don't even know what they're going to receive as a consequence of this. I just want to voice a real sincere thank

• 2:36:44Andrew D. Huberman?

  you for that effort. It's like your lab and your work matters and that's a really special and unique thing.

• 2:36:52Speaker 07

  I appreciate that. I had a good colleague, in fact, shared some grant support under the multi-PI system years ago and she, she actually took a job at NIH as a, as a review officer. And I remember her telling me, you know, and she actually left when she had multiple R01s. So it's like she didn't.

• 2:37:10Andrew D. Huberman?

  Those R01s are kind of the, the bread and butter, big, big grants that every, every card carrying, it's a mark of respect in our community to have one or several of these.

• 2:37:21Speaker 07

  Yeah. Yeah. Yeah. I mean, you know, and it's like you, you eat what you kill in academia. It gets to what we're talking about later. It's like you don't make more money by pulling more grants, but you're able to pay the salary that like the university doesn't pay you your salary. You're, it goes through them.

• 2:37:36Andrew D. Huberman?

  Right. You're just able to do more work.

• 2:37:38Speaker 07

  Yeah. And you're able to like, and if you don't pull in the grants to cover your salary, your job can come to an end, even if you're. Tenured at a place like Hopkins, they can do tricks like slowly lower your salary over these.

• 2:37:51Andrew D. Huberman?

  Or they just let, escort you, or they just take away your space.

• 2:37:53Speaker 07

  Yeah, they put you in a closet and give you no support for trainees and basically make life hell for you. So you could drive a cab in Baltimore and call yourself a full professor at Hopkins, truthfully, but you may have no ability to get anything done.

• 2:38:08Andrew D. Huberman?

  I'm sure you're out there.

• 2:38:09Speaker 07

  But, um, but yeah, I remember one of the things this colleague said, who is successful, but left on top said, "I really don't know that I'm making a difference in the world." And she did some great memory research and, and, and, and connected to drugs, also connected to aging, but she, she said, "I don't, you know, I don't, I don't feel the impact of what I'm doing in the real world." And it's, you know, unfortunately there for a lot of academia, what we do, it stays in the Ivor Tower, you know, the world is a, you know,

• 2:38:35Andrew D. Huberman?

  Not anymore.

• 2:38:36Speaker 07

  It's a beautiful but messed up place. And like a lot of this doesn't disseminate and, and, and because of the various structures, the way the world is set up and thankfully this, I mean, because the work that, that our group, as well as a, a few others around the, the world over the last 20 years, it's like, you do have an emerging psychedelic startup industry now with billions of dollars of investment. And yeah, that's gonna turn into both good and bad, like, you know, it's upping the ante. Like, there's gonna be a lot of good and bad that comes from that, but any new technology is gonna result in that. But we've got psilocybin designated for two separate entities as a breakthrough therapy by the FDA, and people may not realize, and MDMA is designated as a breakthrough therapy

• 2:39:21Speaker 07

  for M, for PTSD. This is a really big deal. That's a very high, I mean, pharma companies would pay millions of dollars to get their new drug a designation like that. And what it means is it's, is early research is saying it shows a high potential for treating disorders that don't have very good treatments. So we're, and we're probably, again, a few years away from both MDMA and probably a year or two after that, psilocybin being treated for PTSD and depression respectively. This is, you know, we have to wait for the phase three studies, but if the results hold up, even if the effect size is like halved of what we're seeing now, it's still gonna be a lot larger than what you're seeing with the traditional medications.

• 2:40:05Speaker 07

  And so it's gonna be approved if the data hold up, and it probably will from my judgment. So.

• 2:40:12Speaker 07

  I feel like what I'm doing is actually having a positive impact in the world in a way that, and I feel, I feel lucky that I got interested in an area that happens to plug into a place in the world where there is that opportunity, where some, you know, great colleagues and friends are focused on areas where I wish they had the opportunity for their work to be disseminated. I wish, I mean, I was lucky to be interviewed on 60 Minutes because of this work. And I was like, oh my God, I know so many, there's a bit of, you know, imposter syndrome, like, oh my God, I know so many scientists that deserve, you know, more so than me to be, have that level of exposure. But if you happen to be

• 2:40:53Speaker 07

  in that place where it's, you gotta do your best to make it work, to take advantage of that luck and that intersection of the world and to push it. And, you know, I've been lucky, but also did take a bit of a leap of faith early on. I did have some, you know, advisors that told me like, you've got a really promising pedigree early on, like, are you sure you want to focus much time on this psychedelic stuff?

• 2:41:17Andrew D. Huberman?

  You've been, you've embraced risk. I mean, I think that, I mean, the world's changed since in 2020, certainly, but, you know, channels like social media, podcasts and things of that sort, you know, your exposure is, is because people are interested in these topics. And that's why people like myself are, are interested in talking to you. I mean, you know, at Stanford, there are now a few labs starting to explore psychedelics more at the mechanistic level. But, so in animal models, excellent labs. But also, I can imagine in, because of the pioneering work that you've done at Hopkins, it'll start to become more common. I'm certain that people are going to have questions about how to

• 2:41:58Andrew D. Huberman?

  get in contact with you and learn more. If people have trauma, PTSD, depression, you know, you, it's likely that they're going to start seeking ways in which they can potentially participate in clinical trials. You're very active on Twitter. Active, I should say. You've got other obligations, but where you are active on social media, you're active on Twitter. It's drug, it's at drug underscore researcher.

• 2:42:24Speaker 07

  Right, right, right.

• 2:42:26Andrew D. Huberman?

  Okay.

• 2:42:26Speaker 07

  Drug underscore researcher. That's how to find me.

• 2:42:30Andrew D. Huberman?

  Great account, by the way. Matthew and I recently got into a dialogue there about some of the deeper effects of psychedelics in the literature versus how they're being discussed in the general public. And I follow his account. It's a really wonderful account for whether or not you have a science background or not. If people are, and I'm going to try and persuade you to be more active on Instagram, but I don't know if I'll succeed in that.

• 2:42:54Speaker 07

  I'll try to get my Instagram game going on.

• 2:42:56Andrew D. Huberman?

  You're a busy guy, and I get it. I'm running a lab too. I get it. You're busy. But, but drug underscore researcher there as well.

• 2:43:02Speaker 07

  Same handle.

• 2:43:03Andrew D. Huberman?

  Same handle. Your lab at Hopkins is pretty straightforward to find through a Google search of your name, Matthew Johnson, Johns Hopkins University. Are there portals for people to, to explore clinical trials, participation in clinical trials of various?

• 2:43:19Speaker 07

  Yeah. And so in our group, so you go to hopkinspsychedelic.org. That's the website. And if you can't remember that, just Johns Hopkins Psychedelic.

• 2:43:29Andrew D. Huberman?

  Yeah, we will provide a link.

• 2:43:30Speaker 07

  Yeah. And you're going to find us. It'll be the first thing that pops up. And we have, trust me, if we have a study on something, it's going to be on that website.

• 2:43:39Andrew D. Huberman?

  That means he's being very polite. So I will be a little bit more aggressive and say, don't email him directly. He won't see that email. Wait until there's a posting for a study and then sign up through the correct portal.

• 2:43:50Speaker 07

  Right. And I try to get back to those emails, but frankly, and it's a, it's because, you know, I'm lucky the area has taken off so much, but there are many days where I simply get so many requests that I can't get through my day.

• 2:44:03Andrew D. Huberman?

  You have to do the research.

• 2:44:03Speaker 07

  Yeah, if I answer all the, so, so, yeah, trust me, if there, and something that a lot of folks don't get in being in academia like we are, it's easy to forget how people don't, understandably don't realize this. This is experimental research. It's FDA approved as an experiment. You know, so we're working towards formal FDA approval for straight up clinical use. But right now, someone can't bring me a case of some idiosyncratic thing and, and say I'm suffering from this complex constellation of depression. Yeah, I'm not a clin- and even if I was, I wouldn't be able to treat them with psilocybin or, or to send them anywhere that was legal to, to, to, to, to take it.

• 2:44:45Speaker 07

  You know, so if, if, if we're gonna be treating you, it's, it has to be, or anyone else in the United States, or most other countries for that matter, it's gonna have to be under the guise of a very specific protocol. This number of milligrams to treat PTSD, to treat major depressive disorder, to treat, um, you know, treatment resistant, um, tobacco use disorder, so nicotine addiction. Very specific studies. This is not one-off treatment. And folks say like, oh, I can pay to go out to Baltimore if you see, oh, my son has this, you know, complex, like in, in their tragic cases, but you, you, so if you're interested in a study, go to our website. If it's not on their website, you know, we don't have

• 2:45:28Speaker 07

  a study on it. There are gonna be forthcoming studies, so I'm gonna be starting studies on opioid addiction and PTSD and an LSD study for chronic pain. The day that those are open for recruitment, they're gonna be up on our website. So that's where you look, um, to see everything. And in fact, I would just recently, a couple of days ago, put up a couple of survey studies, also where we, um, post links to our survey studies. So if you've, if you've had psychedelics and you've taken them for therapeutic intent, intent for PTSD or for depression or anxiety, you can find a link. And also, if you've done breath work for those reasons, we have a link for a study of that type up there now, which is a, a holotropic style, very psychedelic type of, Interesting. of, of, of, of breathing technique that can lead to some of these similar experiences.

• 2:46:11Speaker 07

  So it's up there. More broadly, outside of our group, because there's a growing number of, of groups in the US doing this, and in Europe, doing this research. But you can go to, to clinicaltrials.gov. And if you look in for the the main search term of psilocybin or MDMA or psychedelic plugin, those terms, you can get a list of the growing number. I mean, I think there's, I think there's over forty, maybe it's been a while, there might be over fifty now, I don't know, but studies with just psilocybin going on right now on clinicaltrials.gov. So check out clinicaltrials.gov to see what's going on. But it's gonna be, if you're gonna do anything legal, it's gonna be in the context of a very specific study. It's not gonna be

• 2:46:55Speaker 07

  one-off treatment.

• 2:46:57Andrew D. Huberman?

  Right. And I should say, not just legal, but also supported in the right framework that you described of having a team, etc. Obviously, people will do what they will do. And, um, oh, yeah.

• 2:47:12Speaker 07

  I will say, if people, I never encourage people to take drugs of any, I don't encourage caffeine use. Every drug has its risk.

• 2:47:19Andrew D. Huberman?

  I encourage my own caffeine use, but nobody else's.

• 2:47:22Speaker 07

  I'm drinking up right now. This is great.

• 2:47:24Andrew D. Huberman?

  Yeah, this is very strong mate is what we're drinking. It has not led to a alteration in my perception of of self to the extent that we talked about earlier. However, this conversation wasn't a good example of how we can enter a perceptual bubble. I learned so much about psychedelics and the future of this for sake of mental health and other aspects of health. Matt, thank you so much for your time, for your knowledge. And I think you put it best earlier for holding the candle in a very dark time. And then now, there's light.

• 2:47:58Speaker 07

  Thank you. Well, thanks for helping to spread that light. I really appreciate what what you've been doing. This is a great, great medium that you have going on. So thank you for doing it.

• 2:48:09Andrew D. Huberman?

  It's my pleasure. Thank you. Thank you for joining me for my conversation with Dr. Matthew Johnson. If you're enjoying this podcast and learning from it, please subscribe to our YouTube channel. In addition, you can leave comments and suggestions for future podcast topics and guests in the comment section on YouTube. As well, please consider subscribing on Apple and on Spotify. And on Apple, you can leave us up to a five-star review and a comment. Please also check out the sponsors that we mentioned at the beginning of today's episode. That's a terrific way to support our podcast.

• 2:48:42Speaker 02

  Mr. President, my company informed me of the explosion on our rig on October 2nd. Causing massive water displacement and triggering a tsunami. They all heap the blame on me.

• 2:48:51Speaker 03

  Tom Cruise is. Digger got us into this mess, and Digger's gonna dig us up. From the director of Birdman and The Revenant.

• 2:48:58Speaker 04

  What would happen if I stopped drilling? You stop, you freeze in there, that's what.

• 2:49:03Speaker 03

  With great power comes great deniability.

• 2:49:06Speaker 04

  I'm not the first then.

• 2:49:07Speaker 03

  Digger. See the trailer online. Only in theaters October 2nd. Rated R, under 17, not a minute without parent.

• 2:49:12Andrew D. Huberman?

  And last, but not least, thank you for your interest in science.